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9aBBreVIaTIons
AAV adeno-associated virus
Ad adenovirus
bp base pair
CAR coxsackievirus and adenovirus receptor
CBA chicken β-actin promoter
CI cochlear implant
CKI cyclin kinase inhibitor
CLRN1 clarin 1
CMV cytomegalovirus promoter
COS African green monkey kidney cells
CT computerized tomography
DMEM Dulbecco’s Modified Eagle Medium
DNA deoxyribonucleic acid
dB decibel
E embryonic day
EFS human elongation factor 1-a promoter
FCS  fetal calf serum
GBI Glasgow Benefit Inventory 
GFP green fluorescent protein
GHSI Glasgow Health Status Inventory
GJB2 gap-junction protein connexin 26
GJB6 gap-junction protein, beta 6 
HC hair cell
HeLa human cervical cancer cells
Hz hertz
IHC inner hair cell
ITR inverted terminal repeat
LTR long terminal repeat 
MEF mouse embryonic fibroblasts
MRI magnetic resonance imaging
mRNA messenger ribonucleic acid
NSHL non-syndromic hearing loss
OHC outer hair cell
ORF open reading frame
PBS phosphate buffered saline
PCR polymerase chain reaction
PFA  paraformaldehyde
pRb retinoblastoma tumor suppressor protein
PTA pure tone average
QOL quality of life
RNA ribonucleic acid
RP retinitis pigmentosa
ROS reactive oxygen species
RWM round window membrane
Rz ribozyme
SC supporting cell
SGN spiral ganglion neuron
shRNA short hairpin ribonucleic acid
SIN self-inactivating long terminal repeat
STAT1 signal transducer and activator of transcription-1 
USH Usher syndrome
USH1 Usher syndrome type 1
USH2 Usher syndrome type 2
USH3 Usher syndrome type 3 
WPRE Woodchuck hepatitis virus post-transcriptional element
wt wild-type
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Aims: The here presented studies focused on cochlear gene therapy and Usher 
syndrome type 3 (USH3). Study I evaluated the benefits of cochlear implantation 
in Finnish USH3 patients. Study II tested the feasibility of gene transfer through 
an intact round window membrane by means of an in vitro model. Study III 
concentrated on the evaluation of the efficiency and safety of lentivirus vectors in 
inner ear gene transfer. Study IV introduced three AAV-shRNAs (p27, p53, p27+53) 
and focused on exploring the effects of these constructs on the aminoglycoside-
damaged mouse cochlea. Study V evaluated the effects of AAV-delivered anti-clarin-
ribozyme on mouse cochlea. 
Material and methods: Finnish USH3 patients answered three questionnaires 
which evaluated their quality of life after cochlear implantation. We also collected 
data of these patients’ audiological tests and speech discrimination tests from their 
patient records. We developed an in vitro model suitable for cochlear gene transfer 
studies from a detached mouse round window membrane (RWM) and also tested 
the suitability of adeno-associated virus vectors and lentivirus vectors for cochlear 
gene therapy applications in cell lines and in the mouse cochlea.    
Results: The audiological data collected from Finnish USH3 patients showed 
that most of our patients benefited from the cochlear implantation as much as 
implanted patients without visual deficits did. The Glasgow Benefit Inventory 
questionnaire had a positive score, which means that the patients believed that 
their health status had after the implantation improved.
 The isolated mouse RWM was discovered to be a suitable model for the 
study of gene transfer in vitro. The permeability of the RWM was decreased by 
either damaging the cells with AgNO
3 
and trichloracetic acid or by disrupting its 
cells’ tight-junction expression with histamine-glycerol. However, there was no 
influence of these agents observed on the efficiency of the delivery of therapeutic 
agents or genes through the tested RWM.
 GFP transgene delivered by lentivirus vectors was in the cochlea expressed 
in the structural lining cells of the perilymphatic space and in the epithelial cells 
surrounding the scala vestibuli and scala tympani. Structures of the organ of 
Corti showed no GFP expression. We evaluated the safety of lentivirus vectors 
by inspecting peripheral organs for GFP expression, and cochlear sections for the 
presence of lymphocytes. GFP expression was found only in the liver of one mouse. 
Cochlear sections showed only few lymphocytes. 
We studied the effects of AAV-delivered shRNAs on kanamycin-damaged mouse 
cochleae. AAV vector transduced inner and outer hair cells as well as supporting cells. 
Interestingly, we discovered that p53 and p27+53 shRNAs decreased the number 
of apoptotic cells in the cochleae. This may offer protection against kanamycin-
induced cell death.
  The AAV-GFP vector was expressed in the outer and inner hair cells, in 
some cells of the stria vascularis and in vestibular epithelial cells, but not in the 
spiral ganglion. After one month of expression a significantly increased number of 
apoptotic outer and inner hair cells and strial cells could be detected in the AAV-Rz 
group as compared to the AAV-GFP group. The results suggest that the anti-clarin-1 
ribozyme may initiate a process which leads to apoptotic cell death in the cochlea. 
However, the detected apoptotic cell death in the AAV-Rz group could also be an 
unspecific effect due to an unspecific breakdown of mRNA, and not be related to 
clarin-1 loss.
Conclusions: Cochlear implantation is beneficial for USH3 patients and 
improves their quality of life. The detached mouse RWM model is suitable for 
inner ear gene transfer studies in vitro. Manipulation of the RWM with AgNO
3
, 
trichloracetic acid or histamine-glycerol did not increase the permeability of the 
membrane. Lentivirus vectors are safe and can be used in gene transfer into the 
perilymph. Silencing of p53 protein may decrease apoptosis in the kanamycin-
damaged mouse cochlea. AAV-delivered clarin-1 ribozyme may induce apoptosis 
in cochlear hair cells and cells of the stria vascularis. Apoptosis could explain the 
progressive nature of USH3.
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InTroDUCTIon
Hearing loss is the most common sensory deficit in humans. Genetic defects play 
a major part among patients with sensorineural hearing loss. It is estimated that 
one out of 1000 babies is born with a congenital hearing deficit and over half of the 
hearing loss cases detected in children in the prelingual state are caused by genetic 
factors. In adults, hearing loss can be caused by different factors, including noise or 
hazardous chemical exposure, but it is generally thought that also genetic factors 
have a role in adulthood hearing loss. 
Usher syndrome (USH) is an autosomal recessive disorder defined by bilateral 
sensorineural hearing loss and a visual impairment phenotypically similar to retinitis 
pigmentosa (RP). USH is divided into three main clinical types (USH1, USH2 and 
USH3), based on the severity and progression of the hearing impairment, the 
presence or absence of vestibular dysfunction, and the age of onset of RP. The 
most common form of Usher syndrome in Finland is USH3, which comprises 40% 
of all USH cases, suggesting multiple founder effects. USH3 is caused by mutations 
in the clarin 1 (CLRN1) gene.
To date, treatment methods for sensorineural hearing loss are limited to 
rehabilitation with traditional hearing aids or cochlear implantation. An ideal cure 
would be targeted, long-term or permanent, and should cause as little damage as 
possible to the inner ear structure. Cochlear gene therapy studies have focused on 
the use of different types of viral and non-viral vectors. Gene transfer mediated by 
virus-derived vectors is efficient. Viral vectors can carry therapeutic genes and use 
the natural infectiousness of the virus in introducing and expressing genes within 
the target cells. Vector-based gene delivery has been carried out with adenoviruses, 
adeno-associated viruses (AAV), retroviruses, and herpes viruses. The safety of 
virus-based systems needs to be strictly evaluated before they can be considered 
for use in human applications. The risks involved in virus-based traetments are a 
possible distant spread outside the target and also immune reactions in the host.
The present study consists of five original publications. The studies focus on 
Usher syndrome III patients and different methods of cochlear gene therapy.
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reVIeW oF The lITeraTUre
1 the ear and hearinG
1.1 anatomy of the ear 
The ear is a peripheral auditory apparatus. It consists of three elements: outer ear, 
middle ear, and inner ear. 
The outermost part of the outer ear is the pinna. It is composed of an elastic 
cartilage core covered by skin with hair follicles and sebaceous glands. The pinna 
collects sound waves and directs them to the auditory canal which is a passage 
extending from the auricle to the tympanic membrane (Figure 1A). 
The middle ear, also called tympanic cavity, is an air-filled space in the temporal 
bone located between the tympanic membrane and the inner ear. The auditory 
ossicles, called malleus, incus, and stapes, are responsible for the sound transmission 
in the middle ear. They are arranged in a chainlike fashion and connected by small 
ligaments. The malleus is attached to the tympanic membrane and the footplate of 
the stapes is applied to the oval window, an opening of the bony labyrinth, at the 
other end of tympanic cavity. The auditory ossicles are kept joined by the tensor 
tympani and stapedius muscles. The tympanic membrane is oval-shaped with a 
conical depression near the center caused by the attachment of the malleus. The 
eustachian tube connects the middle ear with the nasopharynx (Figure 1A). 
The inner ear is located within the temporal bone. It consists of a bony labyrinth. 
Inside the bony labyrinth is found the membranous labyrinth, a structure which 
includes both the vestibular and auditory systems. The vestibular system consists 
of two sacs called the utricle and the saccule, and three semicircular canals. The 
auditory system consists of the cochlear duct which is situated within a spiral 
bony canal anterior to the vestibular system. The membranous labyrinth contains 
endolymph, a fluid with a high concentration of K+ (about 150 mM in humans) and 
low concentration of Na+ (1 mM). Perilymph, a fluid with high Na+ (140 mM) and 
low K+ (7 mM), is present between the membranous labyrinth and the walls of the 
bony labyrinth (Kierszenbaum, 2002; Raphael and Altschuler, 2003) (Figure 1A).
The semicircular canals are located within the bony labyrinth. The three ducts 
(horizontal, superior and posterior) are connected to the utricle. The endolymphatic 
duct is formed from joined ducts originating from the utricle and the saccule. The 
15
Figure 1. The ear
A) Anatomy of the ear
1. pinna, 2. auditory canal, 3. tympanic membrane, 4. ossicles, 
5. semicircular canals, 6. cochlea, 7. 8th cranial nerve, 8. round window
B) The cochlea
1. scala vestibuli, 2. scala media, 3. stria vascularis, 4. scala tympani
C) The organ of Corti
1. tectorial membrane, 2. outer hair cells, 3. inner hair cell 
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endolymphatic duct ends in the endolymphatic sac, located between the layers of 
the meninges. Small dilations, called ampullae, are found close to the sites where 
the semicircular ducts are connected to the utricle. Each ampulla contains a ridge 
called the crista ampullaris. The sensory epithelium is covered by a gelatinous mass 
called the cupula and located within the crista ampullaris (Kierszenbaum, 2002). 
The sensory epithelium in the semicircular canals consists of two cell types, the 
hair cells and the supporting cells. 
1.2 the cochlea
The cochlea has three parallel spiraling chambers. The cochlear duct, also called 
the scala media, is the central chamber and contains endolymph. The cochlear duct 
is a membranous coiled duct inside the bony cochlea. It has an apex and a base, 
and the duct spirals for about two and two-thirds turns. In a cross section, there 
is along the bottom of the cochlear duct the basilar membrane, above the cochlear 
duct is Reissner’s membrane, and laterally there is the stria vascularis. Endolymph is 
produced by the cells and capillaries of the stria vascularis. The spiral-shaped bony 
core of the cochlea is the modiolus. Above the cochlear duct and along it runs the 
scala vestibuli, starting at the oval window. Below the cochlear duct run the scala 
tympani, ending at the round window. The scala vestibuli and the scala tympani 
meet at an opening, called the helicotrema, at the apex of the cochlea (Figure 1B). 
The sensory epithelium of the cochlea is situated in the organ of Corti. This is 
formed by the inner and the outer hair cells, supporting cells, the tectorial membrane 
and the inner tunnel (Raphael and Altschuler, 2003). The inner tunnel is bordered 
by the outer and the inner pillar cells, which together separate the inner hair cells 
from the outer hair cells (Kierszenbaum, 2002). The inner hair cells are completely 
surrounded by supporting cells but the outer hair cells’ bodies stand free and are 
surrounded by endolymph except at their apical and basal poles (Lim and Kalinec, 
1998).
A single line of inner hair cells extends along the cochlea from the base to the 
apex. The outer hair cells are arranged in three parallel rows and they also extend 
from the base to the apex. A hair bundle, formed by stereocilia, extends from the 
apical part of each hair cell (Hudspeth, 1989). The stereocilia contain many fine 
longitudinal actin filaments. The stereocilia of a hair cell are arranged in order 
of increasing length from one side to the other (Raphael and Altschuler, 2003) 
(Figure 1C).
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1.3 the roUnd window membrane (rwm)
The round window is an opening onto the inner ear and it is closed off from the 
middle ear by the round window membrane (RWM). The RWM consist of three 
layers: an outer epithelium, a core of connective tissue, and an inner epithelium. 
The outer epithelium faces the middle ear and consists of a single layer of cuboidal 
cells. Tight junctions can be observed near the surface of these epithelial cells. The 
connective tissue core layer consists of fibroblasts, collagen, elastic fibers, and blood 
and lymph vessels. The inner epithelium faces the inner ear and is composed of 
squamous cells with long lateral extensions (Goycoolea and Lundman, 1997). The 
average thickness of the human RWM is 70µm, whereas the average thickness of 
the RWM of rodents is 10-14µm (Goycoolea et al. 1988).
Early studies on the RWM suggested that its role was to release mechanical 
energy and/or conduct sound to the scala tympani (Wever and Lawrens, 1948). 
After learning more aboout the anatomy of the RWM, it has been postulated that 
the RWM could also be involved in secretion and/or absorption (Miriszlai and 
Benedeczky, 1978; Richardson et al., 1971). Especially the outer epithelium, with 
microvilli and abundant cell organelles such as mitochondria, rough endoplasmic 
reticulum and Golgi complex, should be able to play a part in metabolic activities 
and transport.
The permeability of the RWM has been studied extensively in animal experiments. 
These studies have shown that even though the RWM is three-layered it behaves 
more like a semipermeable membrane. Antibiotics, antiseptics, arachidonic acid 
metabolites, local anesthetics, toxins, albumin, cationic ferritin, horseradish-
peroxidase, 1µm latex spheres, and neomycin-gold spheres have been shown to 
pass through it. The permeability of the RWM is influenced by factors such as 
size, configuration, concentration, liposolubility and electric charge of the passing 
material, and the thickness of the membrane (Goycoolea et al., 1988). Transfer 
through the RWM can occur by diffusion through the cytoplasm (e.g. exotoxin), in 
pinocytotic vesicles (e.g. cationic ferritin), or through channels between cells (e.g. 
latex spheres) (Goycoolea, 1995).   
Inflammation in the middle ear mucosa causes changes in the permeability of the 
RWM. It decreases during inflammation due to swelling in the RWM (Goycoolea, 
1992). These changes protect the inner ear during inflammation. The permeability 
of the RWM seems to decrease after AgNO
3
, trichloracetic acid and histamine-
glycerol treatments, thus, these will not enhance the delivery of therapeutic agents 
or transgenes into the inner ear through an otherwise intact RWM (Aarnisalo et al., 
2006). A recent study by Wang et al. showed that administration of collagenase I or 
II to the RWM of a guinea pig partially digested the membrane and allowed adeno-
associated virus (AAV) vectors to pass though the RWM in vivo (Wang et al. 2011). 
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1.4 soUnd transdUction
Sounds are pressure changes that spread through the air. A sound’s frequency is 
measured in Hertz (Hz) and its intensity in decibels (dB). Sound is a mixture of pure 
tones and each pure tone results from sinusoidal waves of a particular frequency. 
Pure tones are characterized by their frequency, but also by their amplitude and 
phase. Normal human ear is sensitive to pure tones with frequencies between 20 
to 20000 Hz. The main frequencies used during speech are between 300 and 3500 
Hz with an intensity of 65 dB (Berne and Levy, 2003). Sounds exceeding 85 dB 
may cause damage to the auditory system. The ear detects sound waves traveling 
in air but the neural transduction mechanism detects fluid movements within the 
cochlea (Berne and Levy, 2003). The acoustic impedance of water is much higher 
than that of air which is the reason for why the ear needs a special apparatus for 
impedance matching (Berne and Levy, 2003). 
Sound waves pass through the auditory canal to the tympanic membrane. The 
moving sound pressure wave causes an inward movement of the membrane. This 
causes the chain of ossicles (malleus, incus, and stapes) to move. The footplate of 
the stapes pushes into the membrane of the oval window, the movement of which 
moves the perilymph within the scala vestibuli. The pressure wave moves within the 
perilymph and is transmitted through the basilar membrane of the cochlea to the 
scala tympani. As a consequence of this the membrane of the round window bulges 
into the middle ear. The tympanic membrane and the chain of ossicles function as 
an impedance matching device (LeMasurier and Gillespie, 2005). Factors which 
influence this impedance matching are: 1) the ratio of the surface area of the tympanic 
membrane to that of the oval window, and 2) the mechanical advantages of the 
lever system formed by the ossicle chain (Berne and Levy, 2003). The movement 
of the fluid in the cochlea leads to vibrations of the basilar membrane which causes 
the hair cells of the organ of Corti to move with respect to the overlying tectorial 
membrane. This movement of the hair cells causes their stereocilia to be bent, which 
in turn opens ion channels. As a result the hair cells excite the primary afferent 
neurons whose axons run in the 8
th
 cranial nerve (Lim and Kalinec, 1998; Raphael 
and Altschuler, 2003). 
A hair cell is a mechanoreceptor. This receptor uses the energy contained in a 
mechanical stimulus to open the ion channels which produce an electrical response 
(Hudspeth, 1989). The basilar membrane’s vibration stimulates hair cells and this 
initiates mechanotransduction. Traveling waves of different frequencies peak at 
different positions along the basilar membrane, as a result each excite a certain 
subset of hair cells. The actual transformation of the mechanical stimuli to electrical 
signals occurs in hair bundles. The bundle is extremely sensitive to mechanical 
stimuli; variations of less than the diameter of an atom are sufficient to initiate 
mechanotransduction (LeMasurier and Gillespie, 2005). The key to the hair bundles’ 
function is their form (Hudspeth, 2005). At the tip of a stereocilium, two or three 
19
Figure 2. Schematic presentation of the auditory pathways
C: cochlea; CN: cochlear nuclei; SON: superior olivary nuclei; IC: inferior colliculus; MGN: medial geniculate 
nucleus; PAC: primary auditory cortex
molecular filaments extend diagonally upward to an insertion on the side of the 
longest adjacent stereocilium. The stereociliary tips are pulled together by tension 
on the elastic tip links. When the hair bundle moves toward its tall edge, the motion 
between adjacent stereocilia increases the tension in each tip link. This is defined as 
a positive stimulus and the tension in the tip link opens one or a few ion channels, 
allowing an influx of K+ and Ca2+ and causing a cellular depolarization (Hudspeth, 
2005). The influx of K+ is a manifestation of the unusually high K+ concentration in 
the endolymph. The receptor current is furthermore enhanced by the endolymph’s 
extracellular potential of +80 mV, which gives rise to a +150 mV electrical driving 
force for K+ and Ca2+ entry (LeMasurier and Gillespie, 2005). As hair cells depolarize, 
voltage-dependent Ca2+ channels near the basolateral synapses open. Increased 
Ca2+ levels stimulate the neurotransmitter release at the glutamatergic synapses, 
initiating signal transmission to afferent neurons (LeMasurier and Gillespie, 2005; 
Ottersen et al., 1998).
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1.5 aUditory circUits
Hair cells (HCs) transmit the information about the timing, frequency and intensity 
of sounds to ribbon synapses of the spiral ganglion neurons. The primary receptor 
cells are the inner hair cells (IHCs) which lie closest to the spiral ganglion cell bodies. 
The outer hair cells’ (OHCs’) role is to improve the sensitivity of sound detection. 
Spiral ganglion neurons (SGN) are subdivided into two classes: Type I and Type 
II. In the mouse, each IHC connects with 10–20 Type I SGNs, but each Type I 
SGN receives input from only one hair cell (Meyer et al., 2009). The Type I SGNs’ 
axons project into the hindbrain, where they bifurcate and make connections with 
multiple cells in the cochlear nucleus (Fekete et al., 1984; Ryugo, 2008). Type II 
SGNs connect to multiple OHCs. In the central nervous system, the Type II SGNs 
axons terminate within the small cell cap in the cochlear nucleus (Brown et al., 
1988). Even though it is known that Type II SNGs receive synaptic input from 
OHCs, their actual function is poorly understood (Weisz et al., 2009). 
In the cochlea, HCs and neurons are topographically arranged according to sound 
frequency: HCs located at the basal part of the cochlea detect higher frequencies 
while HCs located at the apical part detect lower ones. This tonotopic structure of 
the cochlea is preserved in the arrangement of the SGNs, in the organization of 
the central projections into the hindbrain, and throughout every stage of auditory 
processing from brainstem to the cortex (Kandler et al., 2009).
From the cochlear nuclei the input goes to the superior olivary nuclei, where 
the first binaural interactions occur, and to the inferior colliculus. Axons from cells 
of the inferior colliculus go to the medial geniculate nucleus in the thalamus. The 
axons from the geniculate nucleus terminate in the primary auditory cortex (Kandell, 
Schwartz, Jessell, 2000). (Figure 2)
1.6 deVelopment and strUctUre of the moUse cochlea
The mouse inner ear develops from a thickening of the ectoderm known as the otic 
placode. On embryonic day (E) 10, a tube-like structure known as the endolymphatic 
duct projects dorsally from the medial part of the otocyst. On E12, the cochlea adopts 
a more elaborate shape consisting of a proximal and a distal part. The proximal 
part of the cochlea expands further ventromedially and the distal part continues to 
coil. The development of the cochlea ends on E15 (Morsli et al., 1998).
The mouse cochlea is structurally similar to the human cochlea. The evident 
difference is its size. For example, the volume of human endolymph is 7.7 µl and 
of the perilymph 79.5 µl whereas the volume of mouse endolymph is only 0.19 µl 
and of the perilymph 0.62 µl (Jahn and Santos-Sacchi, 2001). Since the molecular 
basis of hearing is poorly understood, it is at the moment difficult to investigate the 
differencies in hearing at the molecular level between humans and mice any further. 
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2 hereditary hearinG loss
Hearing loss is the most common birth defect and affects an estimated 22.5 million 
Europeans (Dror and Avraham 2009). Approximately 8000 Finnish persons are 
deaf (The Finnish Association of the Deaf; www.kl-deaf.fi). One of every 500 
newborns shows bilateral permanent sensorineural hearing loss, and by adolescence 
the prevalence increases to 3.5. per 1000 (Morton and Nance 2006). Over half of 
the prelingual deafness cases are genetic, and these most often autosomal recessive 
and nonsyndromic. Half of the nonsyndromic autosomal recessive hearing loss 
cases can be attributed to the disorder DFNB1, which is caused by mutations in 
the GJB2 gene (DFNB1A) and the GJB6 gene (DFNB1B). A small percentage of the 
prelingual deafness cases are syndromic or autosomal dominant nonsyndromic. 
In the general population the prevalence of hearing loss increases with age. In the 
elderly, hearing loss can be caused by different factors, for example environmental 
ones, but genetics have some influence on it. 
Hearing loss can be classified in different ways. Typically the classification is 
made according to the cause of the hearing loss or by its normal characteristics 
such as age of onset or severity (Gürtler and Lalwani, 2002). The most common 
way to classify hereditary hearing losses is to determine whether the hearing loss is 
syndromic or nonsyndromic (Gürtler and Lalwani, 2002). Patients with syndromic 
hearing loss have an inherited hearing impairment together with some other clinical 
abnormalities, whereas patients with nonsyndromic hearing loss show only impaired 
hearing. Both phenotypes, syndromic and nonsyndromic, can result from mutations 
in the same gene (Keats and Berlin, 1999). This represents the heterogeneity of 
hereditary hearing loss.  
In order to function properly, the ear needs to have its normal anatomical 
structure. However, there are many genes involved in hearing, and the genetics 
of hearing loss is extraordinarily complex (Schrijver and Gardner, 2006). A rough 
estimate is that in the biology of hearing there are several hundred genes involved 
(Friedman and Griffith, 2003). Inherited hearing loss can be autosomal recessive 
or dominant, X-linked, or mitochondrial. Mitochondrial mutations are inherited 
from the mother and the mutation is present in almost all mitochondria (Schrijver 
and Gardner, 2006). It has been thought that mitochondrial mutations are also 
involved in the progressive hearing loss associated with aging (Sinnathuray et al., 
2003) as well as in both syndromic and nonsyndromic forms of hearing loss.
2.1 nonsyndromic and syndromic hearinG loss
Most of the hereditary hearing loss cases (~70%) are nonsyndromic. The pattern 
of inheritance in hereditary hearing loss can be autosomal recessive, autosomal 
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dominant, X-liked, Y-linked, or mitochondrial. Autosomal recessive inheritance 
accounts for 80% of the nonsyndromic hearing loss (NSHL) cases and is the most 
common cause of genetic deafness (Petersen and Willems, 2006). Autosomal 
dominant inheritance is less common, accounting for 20% of the cases (Petersen, 
2002). Sex-linked (Petersen et al., 2008) and mitochondrial (Kokotas et al., 2007) 
forms are much rarer. X-linked inheritance accounts for 1-5% of genetic hearing 
loss cases. Y-linked inheritance has been described by Wang in an extended seven 
generation Chinese pedigree (Wang, 2004). It has been estimated that mitochondrial 
inheritance is responsible for less than 1% of hearing loss cases (Kokotas et al., 2007). 
The phenotypes of different forms of inherited hearing loss vary strongly. People 
displaying nonsyndromic autosomal-recessive inheritance show prelingual onset 
and the hearing loss is from severe to profound due to cochlear defects (Petersen 
and Willems, 2006). Nonsyndromic autosomal-dominant forms show a less severe 
phenotype. The onset is typically postlingual, the severity is from moderate to severe, 
and the hearing loss is progressive (Petersen, 2002). In X-linked traits the onset 
is in males earlier and the hearing loss also more severe than in females who are 
carriers of the trait (Petersen et al., 2008). The Y-linked form affects only males, 
the onset is postlingual, and the hearing loss is from mild to severe and progressive 
(Petersen et al., 2008). In mitochondrial hearing loss the onset is postlingual, the 
severity ranges from normal hearing to profound deafness, and the hearing loss is 
usually progressive (Kokotas et al., 2007).
Individuals with NSHL show all the same phenotype, which makes it hard to 
identify all the different genes responsible. Because of the uniform phenotype it 
was thought for a long time that nonsyndromic deafness resulted from genes which 
were only expressed in the cochlea (Gürtler and Lalwani, 2002). It is possible to 
divide deafness-associated genes into groups on the basis of the proteins they encode 
and the functions they have. These groups include extracellular matrix proteins, 
cytoskeletal components, transcription factors, cellular trafficking proteins, proteins 
involved in ion homeostasis, receptors, and proteins of unknown function (Gürtler 
and Lalwani, 2002; Schrijver and Gardner, 2006).
The first recessive nonsyndromic deafness locus DFNB1 was found in 1994 in 
chromosome 3q11-q12 (Guilford et al., 1994). DFNB1A is caused by a mutation 
in the GJP2 gene. The GJP2 gene encodes connexin 26, a gap-junction protein 
of the β-group which has a role in ion transportation between cells in the cochlea 
(Schrijver and Gardner, 2006). Mutations in the GJP2 gene are responsible for over 
50% of the autosomal-recessive deafness cases in the USA and Europe (Schrijver 
and Gardner, 2006). Today, at least of 64 genes have been identified and 125 loci 
been mapped for autosomal recessive and autosomal dominant hearing loss; three 
genes and 5 loci are associated with X-linked inheritance; the gene associated with 
Y-linked inheritance is still unknown, but one locus has been mapped; 11 genes are 
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associated with mitochondrial inheritance (Hereditary Hearing Loss Homepage; 
http://hereditaryhearingloss.org). 
      15-30% of all hereditary hearing loss cases are syndromic. There are 
hundreds of reported syndromes with impaired hearing as a symptom (Dror and 
Avraham, 2009). The inheritance patterns of syndromic hereditary hearing loss 
can be classified into three distinguishable groups. The first group is comprised 
of syndromes with cytogenetic or chromosomal anomalies, the second group is 
characterized by syndromes which are transmitted by classical monogenic or 
Mendelian inheritance, and the third group shows syndromes with multifactorial 
influences in which the phenotype of the syndrome results from a mixture of genetic 
and environmental factors (Gorlin et al., 1995). Usher Syndrome (Saihan et al., 
2009), Goldenhar Syndrome, Treacher Collins Syndrome (Horbelt CV, 2008), 
CHARGE (Sanlaville and Verloes, 2007), Pendred Syndrome (Glaser B, 2003), 
Jervell and Lange-Nielsen Syndrome (Bitner-Glindzicz and Tranebjaerg, 2000), 
Stickler Syndrome (Admiraal et al.,2002), Waardenburg Syndrome (Read AP, 
2000), Branchio-Oto-Renal Syndrome (Kochhar et al., 2007), Norrie disease (Berger 
W, 1998), and Alport Syndrome (Kashtan CE 1999) are all examples of syndromes 
associated with hearing impairment.
2.2 Usher syndrome
Usher syndrome (USH) is an autosomal recessive disorder which is defined by 
bilateral sensorineural deafness and retinitis pigmentosa, a progressive degeneration 
of the retina that leads to loss of night vision, restriction of the visual field and 
blindness (Bayazit and Yilmar, 2006; Keats and Savas, 2004; Petit C., 2001). In 
addition, variable vestibular dysfunctions are also related to it (Pakarinen, 1995). 
The prevalence of Usher syndrome is 3.5- 6.2 per 100 000 in different populations 
worldwide (Saihan et al., 2009, Yan and Liu, 2010). Over half of the individuals who 
are both deaf and blind are afflicted with Usher syndrome (Boughman et al., 1983). 
2.2.1 Usher syndrome subtypes
Usher syndrome is clinically heterogeneous and it has been divided into three 
subtypes: Usher type I (USH1), type II (USH2) and type III (USH3). 
USH1 is the most severe form and characterized by severe to profound congenital 
sensorineural deafness, constant dysfunction of the vestibular system and onset of 
retinitis pigmentosa in childhood (Petit C, 2001). 
Individuals with USH2 show a mild hearing loss for low frequency and severe 
hearing loss for high frequency sounds; vestibular dysfunction is absent. The visual 
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impairment develops progressively and the onset of retinitis pigmentosa occurs in 
puberty. Over half of all USH patients have USH2 (Eudy et al., 1998; Petit C, 2001). 
In USH3 the hearing loss is progressive and the individuals may suffer from 
vestibular dysfunction. The onset of retinitis pigmentosa and the degree of vestibular 
dysfunction vary among those affected (Keats and Savas, 2004). USH3 is rarest 
from of the syndrome in most populations except in Finland (Pakarinen et al., 1995) 
and among Ashkenazi Jews in various regions (Ness et al., 2003). In Finland USH3 
is the most common form of Usher syndrome (Figure 3). It comprises 40% of all 
Finnish USH cases, suggesting multiple founder effects (Karjalainen et al., 1989; 
Pakarinen et al., 1995).
2.2.2 USH genes
To this day, 12 chromosomal loci with nine different USH gene products have been 
identified:
• USH1B is caused by mutation in MYO7 (encodes protein myosin VIIa) (Weil 
et al., 1995 nature)
• USH1C by mutation in USH1C (encodes harmonin) (Verpy et al., 2000)
• USH1D by mutation in CDH23 (encodes cadherin 23) (Bolz H et al., 2001) 
• USH1E by unknown gene (Chaïb 1997)
• USH1F by mutation in PCDH15 (encodes protocadherin 15) (Ahmed et al., 
2001; Alagramam et al., 2001; Wayne et al., 1996)
• USH1G by mutation in USH1G (encodes scaffold protein containing ankyrin 
repeats and SAM domain [SANS]) (Weil et al., 2003)
• USH1H by unknown gene (Ahmed et al. 2009)
• USH2A by mutation in USH2A (encodes usherin) (Eudy et al., 1998; van 
Wijk et al., 2004)
• USH2C by mutation in VLGR1 (encodes very large G-protein-coupled 
receptor 1) (Weston et al., 2004); 
• USH2D by mutation in WHRN (encodes whirlin) (Ebermann et al., 2007) 
• USH3A by mutation in CLRN1 (encodes clarin 1) (Adato et al., 2002; 
Joensuu et al., 2001; Sankila et al., 1995). 
• USH3B by unknown gene (Chaïb 1997)
The USH1A locus was reported in 1992 (Kaplan et al., 1992) but was demonstrated 
to be a linkage artifact in 2006 (Gerber et al., 2006). PDZD7 is a USH modifier gene. 
Mutated PDZD7 affects the USH phenotype only when combined with mutated 
USH2A or VLGR1b (Ebermann et al., 2010). 
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Figure 3. Usher syndrome type III
Map of Finland showing the birthplaces of USH3 patients’ grandparents
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It has been suggested that USH proteins form a network which has a critical role 
in the development and maintenance of the sensorineural cells in both the inner 
ear and the retina (Adato et al., 2005; Kremer et al., 2006; Maerker et al., 2008; 
Reiners et al., 2005, 2006; Tian et al., 2009). The functions of the USH proteins 
are, though, still poorly known. 
2.2.3 USH3
USH3 is caused by mutations in the CLRN1 gene, which encodes transmembrane 
protein clarin 1 (CLRN1). CLRN1 is assumed to have four transmembrane domains, 
and it shares a homology with tetraspanin family (Adato et al., 2002) (Figure 
4). It is predicted to be related with ribbon synapses of cochlear hair cells and 
photoreceptors, and has been suspected to be involved with the cytoskeleton (Geng et 
al., 2009; Tian et al., 2009; Zallocchi et al. 2009, 2012). Eighteen CLRN1 mutations 
have been documented (Aller et al., 2004; Eberman et al., 2007; Herrera et al., 
2008; Joensuu et al., 2001; Ness et al., 2003; Sadeghi et al., 2005). 
Finnish USH3 patients show two mutations: p.Y176X (Finnish founder mutation) 
and p.M120K (in combination with the founder mutation). In USH3 patients in 
Ashkenazi Jews the founder mutation is p.N48K (Adato et al., 2002; Fields et al., 
2002; Ness et al., 2003). 
Figure 4. Schematic presentation of clarin 1
TM: transmembrane domain
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2.3 cUrrent treatment options for hereditary hearinG loss
Currently the rehabilitation options for patients with severe to profound hearing 
loss are traditional hearing aids or cochlear implants (CI). A CI is a device which 
electrically stimulates cochlear nerve fibers. Enhancement of the capabilities of 
cochlear implant devices is an approach to the treatment (Shibata and Raphael, 
2010). Although the current therapeutic possibilities are still limited, in some cases, 
such as in auditory neuropathy, a molecular diagnosis is worthwhile. It is estimated 
that approximately 40% of the auditory neuropathy cases have an underlying genetic 
basis (Manchaiah et al., 2011). In auditory neuropathy the function of the outer 
hair cells is normal, but the inner hair cell and/or the auditory nerve function is 
disrupted. Cochlear implantation in children with auditory neuropathy shows mixed 
results (Mason et al., 2003; Teagle et al., 2010). CIs bypass the cochlear sensory cells 
but are of limited use when the lesion is further upstream on the afferent auditory 
pathway. To overcome this problem, Wise et al. injected adenoviral vectors with 
neurotrophins in order to stimulate a resprouting of the auditory peripheral fibers 
required for the electrical stimulation of spiral ganglion neurons (Wise et al., 2010).
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3 cochlear Gene therapy
The methods of cochlear gene therapy are at present under energetic development. 
At the moment the only efficient way of treating hearing disorder originating from 
the inner ear is rehabilitation with traditional hearings aids or cochlear implantation 
(Lalwani et al., 2002a,b). Cochlear gene delivery methods are developed not only 
for future therapeutic methods of hearing improvement but also for the study of the 
molecular basis of deafness which is poorly known. Before cochlear gene therapy 
can be used in humans, it is necessary to develop transfer methods which maintain 
both the hearing function and the cochlear architecture (Lalwani et al., 2002a,b). 
Different viral vectors, plasmids, liposomes, and nanoparticles have been used as 
vectors in cochlear gene therapy studies (Chen et al., 2010; Kesser and Lalwani, 
2009). Recent attempts have focused on the use of various stem cell types for 
repairing the auditory system (Kesser and Lalwani, 2009).
3.1 Viral Vectors
The work of many research groups has resulted in a generation of number of viral 
vectors for various applications in gene therapy. Adenovirus, retrovirus, adeno-
associated virus (AAV), and herpes virus-derived vectors have been tested for 
purposes of cochlear gene transfer in both in vitro and in vivo experiments. Each 
viral vector possesses its own characteristics, with consequences for its uses in 
different applications. 
A number of routes of vector delivery have been established. The delivery 
methods include osmotic minipump infusion or microinjection into the scala 
tympani through the RWM (Aarnisalo et al., 2007; Derby et al., 1999; Jero et al., 
2001a; Komeda et al., 1999; Pietola et al., 2008, 2012; Raphael et al., 1996; Yagi 
et al., 1999), infusion or injection into the scala tympani through a cochleostomy 
(Carvalho and Lalwani, 1999; Han et al., 1999; Lalwani et al., 1996, 1997, 1998a,b; 
Wareing et al., 1999), injection into the endolymphatic sac (Yamasoba et al., 1999), 
injection into the utricle (Praetorius et al., 2002), and application of gelatin soaked 
with the therapeutic agent to the RWM (Aarnisalo et al., 2006; Jero et al., 2001a; 
Wang et al., 2011). All other forms of vector delivery except the gelatin application 
involve damage to the inner ear structures, which increases the risk of hearing 
impairment due to a trauma to the cochlea (Lalwani et al., 2002a,b).
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3.1.1 Adenovirus
Adenoviruses were isolated from human adenoid tissue in 1953 (Rowe et al. 1953). 
Since then, 51 different serotypes of adenoviruses among 6 different species have 
been identified. Classification is based on serological tests, the virus’s ability to 
hemagglutinate red blood cells of rhesus monkey or rat, on restriction, and on 
sequence analysis. Most human adenoviruses do not cause infections in animals. 
Adenoviruses are non-enveloped, icosahedral viruses. A linear, double-stranded 
DNA genome is enclosed in a capsid which is composed of 240 hexon capsomers 
and 12 penton capsomers with spike-shaped protrusions. The capsid also contains 
some hexon- and penton-base-associated proteins. Histon-like viral core proteins 
are responsible for the DNA’s packaging. 
The primary virus attachment to the host cell coxsackie- and adenovirus-receptor 
(CAR) is usually mediated by the terminal globular domain in the virus capsid 
(Bergelson et al., 1999), but also heparan sulfate proteoglycans have been shown 
to promote adenoviral attachment to some cell types (Dechecchi et al., 2001). The 
two common ways of viral entry after the binding to the host cell are clathrin- and 
caveolae/lipid raft-mediated endocytosis. The endosomal uptake of the virus is 
followed by stepwise dismantling of the capsid, which leads to microtubule-assisted 
transport and delivery of the core protein-coated viral genome to the nucleus of the 
host cell (Greber, et al., 1993). The first gene to be expressed is E1A which encodes 
a transactivator for the early genes for transcription (E1B, E2A, E2B, E3 and E4). 
The E2 region encodes proteins needed in the DNA replication (DNA polymerase, 
DNA-binding protein, and precursor of the terminal protein). The virion assembly 
in the nucleus starts approximately 8 hours after the infection and leads to the 
production of 104-105 particles per cell. The new viruses can be released after a 
proteolytic maturation by cell lysis 30-40 hours after the infection.  
3.1.2 Adeno-associated virus (AAV)
The human adeno-associated virus was discovered as a contaminant in an 
adenovirus preparate (Castro et al., 1967). AAV belongs to the Parvoviridae family, 
in a separate Dependovirus genus because AAV needs a co-infecting helper virus for 
a productive infection. Even though AAV is very common in the human population 
(approximately 80% of humans are seropositive for AAV2) it has not been linked 
to any human illness.
AAV is a small, non-enveloped virus with an icosahedral capsid. It has a small 
(approximately 4.7 kilobases), linear single-stranded DNA genome. AAV2 DNA has 
inverted terminal repeats (ITR) which participate in the synthesis of leading-strand 
and double-stranded replicative intermediates. AAV does not encode a polymerase 
enzyme; it rather uses the polymerase of the host cell to replicate its DNA (Ni et al., 
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1998). Between the ITRs are rep and cap genes. The rep gene encodes nonstructural 
proteins needed in replication and the cap gene encodes structural proteins needed 
in capsid formation. 
AAV attaches to the host cells by binding to membrane-associated heparin 
sulphate proteoglycans (Summerford and Samulski, 1998). The internalization of 
the virus is helped by co-receptors (Gonçalves, 2005). The trafficking of AAV inside 
the host cell is not fully understood. Once AAV has entered the host cell nucleus, it 
can follow either the lytic or the lysogenic pathway. The lytic pathway develops in 
cells which are co-infected with a helper virus (for example Ad or herpes simplex 
virus). The lysogenic pathway develops in host cells in the absence of helper viruses. 
When AAV infects a host cell without a helper virus it enters into a latent state, its 
gene functions are suppressed and its genome integrates into the host cell’s genome. 
The latently infected cell can be super-infected with a helper-virus whereupon the 
AAV gene expression machinery is activated. The provirus DNA dissociates from 
the host genome and is replicated and packaged into virions. Helper virus-induced 
cell lysis releases newly formed AAV virions from the host cell (Gonçalves, 2005). 
AAV has at least 10 different serotypes. Even though different serotypes show 
a high amino acid homology, there are discernible differences in their functions. 
AAV serotypes 1, 2, and 3 need heparan sulfate proteoglycans as co-receptors for 
viral entry, whereas serotypes 4 and 5 do not use these co-receptors. AAV serotype 
5 is shown to bind to siliac acid on the target cell’s surface (Walters et al., 2001). 
These properties have to be considered when trying to use AAVs in targeted gene 
transfer. The effects of different serotypes on transduction efficiency in the cochlea 
have been studied by several groups (Bedrosian et al., 2006; Liu et al., 2007; Luebke 
et al., 2009; Stone et al., 2005). Liu et al. reported that serotypes 1, 2, 3, 5, 7, and 8 
transduced only IHCs (Liu et al., 2005). Bedrosian et al. reported a transduction of 
HCs with serotype 1 and 8 after injection into newborn mouse pups (Bedrosian et al., 
2006). Mosaic AAVs, which have both serotype 1 and 2 capsids, transduce IHCs in 
adult mice (Luebke et al., 2009). Conventional AAV vectors contain single-stranded 
DNA, which will be converted into double-stranded DNA before gene expression 
(Ferrari et al., 1996).  Any AAV genome that reaches the nucleus will still require 
the synthesis of a complementary strand in order to achieve gene expression. This 
critical step can be effectively bypassed through the use of self-complementary AAV 
vectors, which achieve faster and stronger transgene expression than conventional 
AAV vectors (Yokoi et al., 2007).  
3.1.3 Lentiviruses
Lentiviruses belong to the Retroviridae family and the lentivirus genus is 
divided into 6 subgenera: bovine, equine, feline, ovine/caprine, primate, and 
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unclassified. The primate lentivirus subgenus contains 3 different species: human 
immunodeficiency virus 1 (HIV-1), human immunodeficiency virus 2 (HIV-2), and 
simian immunodeficiency virus (SIV).
Lentiviruses contain an inner core in which the viral genome and also enzymes 
needed for the initiation of viral replication are situated (Haseltine, 1991). The core 
is surrounded by proteins which form a capsid around the core. The viral envelope, 
i.e. the outer membrane of the virus which is obtained from the previous host, 
consists of a lipid membrane (Haseltine, 1991; Varmus, 1988). Viral glycoproteins, 
which participate in the entry of the virus into a new host cell, are found on the 
surface of the envelope (Haseltine, 1991).     
The lentivirus genome is composed of two single-stranded, polyadenylated RNA 
molecules, and the size of the genome is 9000 to 10000 base pairs (bp) (Clements 
and Narayan, 1981). There are three structural genes in the lentivirus genome: gag 
codes for a group-specific antigen, pol codes for polymerase, and env codes for the 
envelope. Lentiviruses also contain small open reading frames (ORFs) between 
the pol and env genes (Pyper et al., 1986; Zheng et al., 2005). The ORFs code for 
two regulatory proteins and four accessory proteins (Ratner et al., 1985; Zheng et 
al., 2005). The regulatory proteins are the transcriptional protein (Tat) and the 
regulator of virion gene expression (Rev). The accessory proteins are the “negative 
effector” (Nef), the viral infectivity factor (Vif) and the viral proteins r (Vpr) and u 
(Vpu). Long terminal repeats (LTRs) are located at both ends of the RNA strand. 
The LTRs are composed of U3, R and U5 regions. The U3 region contains important 
viral enhancer/promoter elements as well as regulatory elements (Narayan and 
Clements, 1989). The R region at both ends of the RNA strand contains a cap site 
from which transcription of the RNA strand is initiated, also the polyadenylation site 
which creates the poly(A) tail to the developing RNA strand, and the termination 
signal for viral RNA transcription (Hess et al., 1986; Guntaka, 1993).     
Lentivirus infection begins by a high-affinity binding reaction between the surface 
glycoproteins on the viral envelope and CD4 molecules on a host cell (Haseltine, 
1991). The virus enters the host cell by membrane fusion mediated by the viral 
envelope glycoproteins (Haseltine, 1991). Once the virus has entered the host 
cell’s cytoplasm, its RNA is converted into DNA with the help of virus-specified 
RNA-dependent DNA polymerase, which is also known as reverse transcriptase, 
and ribonuclease (Haseltine, 1991). The formed DNA is called a provirus and it is 
integrated into the host genome by a viral enzyme integrase (Haseltine, 1991). The 
viral DNA stays permanently in the host cell genome. The virus rarely kills the host 
cell and the host cells are infected for life (Haseltine, 1991). Lentiviruses utilize, like 
other retroviruses, the host cell machinery to transcribe viral DNA into genomic RNA 
and messenger RNA (mRNA) (Guntaka, 1993; Narayan and Clements, 1989). The 
newly formed pre-mRNA is processed by polyadenylation and splicing (Narayan and 
Clements, 1989). Single viral mRNA is spliced into 46 different products (Purcell 
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and Martin, 1993). Once the viral proteins are fully processed they are assembled 
into virions in the cellular membrane (Nguyen and Hildreth, 2000).
3.2  hair cell manipUlation
Hair cells in the organ of Corti are terminally differentiated and the maintenance 
of their post-mitotic state is essential for hair cell survival. Most of the cochlear 
cells in mice reach their post-mitotic state by E14.5 (Morsli et al., 1998). Almost 
all cell divisions in the developing auditory epithelium of mammals and birds stop 
before birth, and the maintenance of this state requires cyclin kinase inhibitors 
(CKIs) (Harper, 2001). CKIs are divided into two families, the Cip/Kip family which 
includes p21Cip1, p27Kip1 and p57Kip2, and the Ink4 family which includes p16Ink4a, 
p15Ink4b, p18Ink4c and p19Ink4d. At least p21Cip1, p27Kip1, and p19Ink4d regulate cell cycle 
re-entry in the cells of the auditory epithelium. Co-deletion of p19Ink4d and p21Cip1 
leads in mice of an early postnatal stage in hair cells to cell cycle re-entry and a 
formation of supernumerary hair cells. An onset of abnormal proliferation in the 
auditory epithelium leads eventually to a loss of hair cells (Laine et al., 2007). p27Kip1 
has an important role in the developing and also the mature inner ear. p27Kip1 is 
expressed in cochlear supporting cells but not in hair cells. In the supporting cells, 
p27Kip1 acts as a negative regulator of the G1-S transition in the cell cycle (Chen 
and Segil, 1999; Harper, 2001; Löwenheim et al., 1999). Disruption of the p27Kip1 
gene in a knockout mouse model promotes cell proliferation in the organ of Corti 
of both postnatal and adult mice. The deletion of p27Kip1 affects the morphology of 
these sensory cells, and all p27Kip1 knockout mice show severe hearing impairment 
(Löwenheim et al., 1999). The role of different combinations of CKIs in the auditory 
epithelium is only poorly understood. While p27Kip1 is required for the maintenance 
of the post-mitotic state of the supporting cells, other CKIs such as p19Ink4d, p21Cip1 and 
the retinoblastoma tumor suppressor protein (pRb) are acitve in hair cells (Chen et 
al., 2003; Mantela et al., 2005; Sage et al., 2005). pRb is the primary protein involved 
in cell cycle regulation in hair cells, and its function is to repress transcription of 
the genes required for G1-S transition. It is known that an inactivation of pRb 
family members in neurons makes these re-enter the S-phase. This cell cycle re-
entry results in abnormal DNA replication, which is followed by cell death.  p53 
is a tumor suppressor gene which has a major role in DNA damage-induced cell 
death.  p53 is activated when a cell’s DNA repair system fails, and it upregulates 
Bax, a Bcl-2 family member which takes part in cell death regulation. p53 is also 
known to be involved in the initiation of cell death in cochlear and vestibular hair 
cells (Cheng et al., 2005).
Many studies in the field of inner ear therapy have focused on the regeneration 
of hair cells (Collado et al., 2008). The ability of avians to regenerate hair cells 
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(Corwin and Cotanche, 1988; Ryals and Rubel, 1988) has encouraged scientists to 
study the features which make this capacity possible. Elucidation of the mechanism 
of hair cell regeneration may lead to the preservation of the auditory function in 
hearing-impaired patients. Recent advances in hearing therapeutics have also taken 
advantage of stem cells. Embryonic stem cells are pluripotent and the aim is to 
differentiate these cells into hair cell-like structures (Coleman et al., 2007; Oshima 
et al., 2010). In the ideal case embryonic stem cells will be differentiated into fully 
functional cochlear hair cells and be used for a cell-based treatment of hearing loss. 
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aIMs oF The sTUDy
1.  To evaluate the benefits of cochlear implantation on Usher syndrome III 
patients
2.  To test the feasibility of gene delivery through the intact round window 
membrane in an in vitro model
3.  To test the efficiency and safety of lentivirus vectors for inner ear gene 
transfer
4.  To study the effects of adeno-associated virus vector-delivered shRNAs on 
the aminoglycoside damaged cochlea
5.  To evaluate the effects of adeno-associated virus vector-delivered anti-
clarin-ribozyme on the cochlea
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MaTerIal anD MeThoDs
1. sUbJects and samples
1.1 consent and ethics committee permissions (I) 
USH3 patients and their family members were informed of the aims of the study. 
All participants signed a consent form. Research permissions were obtained from 
the Ethics committees of the participating hospitals. 
1.2 Ush3 patients (I)
Altogether 19 Finnish USH3 patients participated in the study. All patients received 
a cochlear implant during the years 1995 to 2005. The mean age of the patients was 
47±19 years (youngest 12 years and oldest 72 years); seven of the patients were male 
and twelve female. Saliva samples for the mutation analysis were collected from 15 
patients; the remaining four patients already had a USH3 diagnosis.  
1.3 patient data and qUestionnaires (I)
A set of three questionnaires was sent to the patients (GBI, GHSI and a questionnaire 
designed for this study). Implantation data, audiometric data, imaging data, and 
data of the ophthalmologic examinations and vestibular tests of each patient were 
collected from medical records.
The GBI is a questionnaire developed to assess the patient’s health status after an 
otorhinolaryngological intervention. The GBI questionnaire consists of 18 questions. 
The responses to all of the questions are averaged, so that all questions carry equal 
weight. The average score is transposed onto a benefit scale ranging from -100 
(maximal negative benefit) through 0 (no benefit) to +100 (maximal benefit). The 
response to each question is placed on a five-point Likert scale ranging from a 
large deterioration to a large improvement in health status. The GBI questionnaire 
produces total score and three subscales: a general subscale, a social support 
subscale, and a physical health subscale.
36
Cochlear Gene Therapy; Viral Vectors, Gene Transfer, and Treatment Strategies for Usher Syndrome
The validated GHSI form contains 18 health status questions. These questions 
evaluate how the health problem has affected the patient’s quality of life at the 
time the GHSI is completed. The response to each question is evaluated on a five-
point Likert scale ranging from high to low health status. GHSI questionnaire also 
produces total score and three subscales: a general subscale, a social support subscale 
and a physical health subscale. 
The questionnaire designed for the present study collected data about the 
implantation, about problems encountered with the use of the cochlear implant, 
previous use of hearing aids, previous and current status of vision, and vision-related 
symptoms. The responses to the questions were evaluated on a five-point Likert 
scale ranging from 1 (poor performance) to 5 (good performance).
Audiometric tests including pure-tone thresholds, speech reception threshold 
and speech recognition were conducted according to ISO standards. The change 
of pure-tone thresholds, calculated over 0.5, 1, 2 and 4 kHz, was derived from 
audiometric measurements made 5-10 years and one year prior to the surgery 
and 6-12 months after the surgery. Word recognition values were obtained 
from all patients by using bisyllabic, phonetically balanced words of the Finnish 
language validated for adults. The status of the patients’ vision before and after the 
implantation was evaluated by four different questions in the questionnaire and by 
data collected from patient records.
1.4 animals and ethics committee permission (II-V)
Wild type CD-1 mice were used in the original the publications II-V. Animal care 
and experimental procedures were approved by the Local Ethics Committee for 
Animal Experiments, University of Helsinki, and the National Animal Experiment 
Board in Finland. The animal experiments were conducted in accordance with the 
European Convention guidelines.
1.5 cell lines (III, IV)
HeLa cell (American Type Culture Collection (ATCC) number CCL-2) cultures were 
used in the lentivirus experiments (III). Testing of the shRNA constructs was done 
in African green monkey kidney cell (COS) cultures (IV).
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1.6 Viral Vectors (II-V) 
Adenovirus vectors, adeno-associated virus vectors and lentivirus vectors were used. 
A summary over all the viral vectors, their promoters, transgenes, and titers are 
presented in Table 1. These vectors were used in original the publications II-V.
Table 1. Viral vectors
Vector promoter Transgene Titer p/ml
Ad5 EFS GFP 2x10^9
HOX (lentivirus) EFS GFP 8.5 x 10^6
WOX (lentivirus) EFS GFP 8.6 x 10^7
AAV2/2 CBA Rz 3.2x10^13
AAV2/2 CBA GFP 7,21x10^12
AAV2/2 U6 shRNA 1x10^12
AAV2/2 CMV GFP 1x10^12
Ad5: adenovirus, serotype 5; EFS: human elongation factor 1-α minimal promoter; GFP: green fluorescent 
protein; AAV: adeno-associated virus (serotype 2/2); CBA: chicken β-actin promoter; Rz: ribozyme; shRNA: 
short hairpin RNA (p27 Kip1, p53, p27 Kip1+p53); CMV: cytomegalovirus promoter. 
Titer particles/ml (p/ml)
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Figure 5. Schematic presentation of the viral vectors used in original publications II-V.
1. Adenovirus, type 5 (II)
2. HOX-GFP, lentivirus (III)
3. WOX-GFP, lentivirus (III)
4. AAV2/2-Rz (V)
5. AAV2/2-GFP (V)
6. AAV2/2-shRNA (IV)
7. AAV2/2-GFP (IV)
ITR: inverted terminal repeat; SIN: self-inactivating long terminal repeat; EFS: human elongation factor 1-α 
minimal promoter; CMV: cytomegalovirus promoter; CBA: chicken β-actin promoter; GFP: green fluorescent 
protein; Rz: ribozyme; shRNA: short hairpin RNA; WPRE: Woodchuck hepatitis virus post-transcriptional 
element; pA: poly adenylation site
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2. methods
2.1 mUtation analysis (I)
DNA from USH3 patients was obtained from saliva samples and extracted with 
OrageneTM kits (DNA Genotek Inc., Ontario, Canada). After DNA extraction, the 
exons of the CLRN1 gene (NM_174878) were amplified with exon specific primers 
(Isosomppi et al., 2009) and Amplitaq® DNA Polymerase, and then purified with 
Exo-SAP (USB, Cleveland, OH, USA). The sequencing reactions were performed 
with an ABI3730 Automatic DNA sequencer using the ABI PRISM BigDye® 
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA). 
2.2 In VItro model (II) 
Cochleae from 30 CD-1 mice were removed and placed into DMEM culture medium. 
The RWM with the intact bony niche was removed under a microscope with a 
diamond micro drill. Detached RWMs were with epoxy glue fixed on a petri dish 
covering a 1mm hole in the dish. A plastic tube was fixed to the dish’s hind side with 
adhesive. This tube was filled with 500µl of PBS. Hyaluronic acid ester (Merogel®, 
Medtronic Xomed) was used as the sponge material.
Figure 6. Schematic presentation of the RWM in vitro model
Redrawn from Aarnisalo et al., 2006
rwm
sample in sponge
fascia
plastic
petri dish
plastic tube
(inner ear side)
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Ten RWMs were treated with AgNO
3
, trichloracetic acid, or histamine-glycerol, 
and prepared for histological analysis. Samples were fixed with 4%PFA o/n, 
decalcified in 0.5M EDTA for 7-10 days, mounted to paraffin and sectioned. The 
samples were stained with hematoxylin-eosin and analyzed under light microscope. 
Samples of phosphate buffered saline (PBS) were collected at different time points 
from the plastic tube (20µl / sample). The absorbance of toluidine blue was evaluated 
spectrophotometrically (590 nm; Multiscan RC, Labsystems).
2.3 shrnas (IV)
Four different pairs of p27Kip1 sequences were designed from Genbank BC014296 
and NM_009875 sequences and synthesized (Oligomer, Finland). The pairs were 
annealed and the generated double-stranded DNA fragments were cloned into the 
pSilencer 1.0-U6 plasmid (Ambion, USA) between ApaI and EcoRI under the U6-
promoter. The p53 shRNA sequences were designed from GenBank: AF051368 and 
synthesized (Oligomer). The annealed fragment was cloned in pSilencer 1.0-U6. 
The created shRNAs were cloned into the AAV-vector either alone (p27Kip1 or p53) 
or together (p27Kip1 and p53).
2.4 pcr (II)
PCR was used for studying the permeability of the detached RMWs for adenoviral 
vector. Five µl of sample was used as template along with 5pmol of forward and 
reverse primers complementary to the GFP transgene. The samples were amplified 
with a PTC-100 thermal cycler using a reaction volume of 20µl. The 408 bp PCR 
product was visualized in 1% agarose gel and its concentration was determined 
semiquantitatively by Kodak Image Station 440CF analyzer.   
2.5 ribozyme (V)
Three hammerhead ribozymes were designed to specifically recognize and cleave 
wild-type mouse clarin-1 mRNA. The ribozymes and the corresponding clarin-1 
RNA oligonucleotide 12-mer substrates were synthesized by Dharmacon (USA). 
Cleavage time course reactions of the hammerhead ribozymes were performed 
under substrate excess conditions at 37ºC in 40 mM Tris–HCl, at pH 7.5 and in 
the presence of either 20 mM MgCl
2
 or 2 mM MgCl
2
. The 12- mer substrates were 
5’-end labelled with gamma 32P-ATP resulting in 7-mer cleavage products.
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2.6 transdUctions in cell lines (III,IV)
HeLa cells were cultured on 13 mm cover slips (Menzel-Gläser, Braunschweig, 
Germany) on 24-well plates (NuncTM, Denmark) in Dulbecco’s modified Eagle’s 
medium (DMEM) (BioWhittaker, USA) supplemented with 5% FCS (fetal calf 
serum) (PromoCell, Germany), GIBCOTM GlutaMAXTM –I Supplement (100x, 
L-Alanyl-L-Glutamine) (Invitrogen, USA), and Penicillin-Streptomycin (100x) 
(Sigma-Aldrich, Germany). The cells were transduced with HOX-GFP and WOX-
GFP, respectively, as follows: 30 000 cells with 1 µl of vector, 40 000 cells with 
5 µl of vector and 50 000 cells with 1 µl of vector. The vectors were gently added 
onto the growth medium with a pipette. The cells were cultured for three, five, and 
seven days at +37ºC in a 5% CO
2
 environment. The growth medium was removed 
and the cells were rinsed with PBS (2 x 600 µl). The cells were fixed in 4% PFA 
(paraformaldehyde, Sigma-Aldrich, USA) in PBS for 5 min, rinsed again in PBS, 
and mounted in Vectashield® Mounting Medium for fluorescence imaging (Vector 
Laboratories, USA). (III)
The silencing effect of the different shRNAs was tested by transfecting 1 µg of 
shRNA-plasmid into COS cells in culture with Lipofectamine or Lipofectamine 
2000 (Invitrogen, USA) reagents according to the manufacturer’s instructions. Since 
proliferating COS cells do not express p27Kip1, we cotransfected 1µg of p27Kip1 cDNA 
expressing vector together with the shRNA plasmids. Bluescript plasmid (Stratagene, 
USA) was used as a control. The expression levels of p27Kip1 in COS cells were 
analyzed from 10 µg of protein from cell lysates with 12% SDS-PAGE acrylamide gel-
electrophoresis and Western blotting using Hybond-C Extra membrane (Pharmacia, 
USA) and rabbit polyclonal anti-p27Kip1 antibody (1:1000; Santa Cruz, USA) together 
with Anti-rabbit Ig-HRP visualized by ECL Western blotting substrate (Pierce, 
USA). The best silencing sequences (shRNAs 2 and 3) were with their respective 
U6 promoters digested out from the pSilencer 1.0-U6 with BamHI and cloned next 
to each other into the AAV-vector (AAV2/2) in front of the woodchuck hepatitis 
virus post-transcriptional element (WPRE). The CMV promoter present in the AAV-
CMV-WPRE construct was removed with EcoRI and XhoI, and uncoding stuffer 
DNA was cloned instead to keep the viral DNA size optimal. As controls for Western 
blotting, we were growing mouse embryonic fibroblasts (MEF) from p53 targeted 
embryos (p53-/- and p53+/-, Jackson laboratory, USA). Western blot analysis was 
performed as above with anti-p53 antibody (1:300; sc-6243 Santa Cruz). (IV)
2.7 animal sUrGery (II-V)
Mice were anesthetized with an i.p. injection of anesthetic (Table 2). Exposure of 
the cranial base and middle ear bulla was performed through a ventral paramedian 
incision as described previously by Jero et al. (2001b). The vectors were injected 
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slowly into the inner ear by a glass capillary (inner diameter 0.5 mm, SM100F-15, 
Harvard apparatus, tip diameter 5 µm) with the help of a microinjector (Narishige, 
Japan) and a preparation microscope (Olympus SZX12). After the injection, the 
RWM was sealed with a small piece of thin fascia and the incision was closed in 
layers. The total operating time was approximately 15-20 min.
Table 2. Anesthetics
II, III Midazolam 2mg/kg(Midazolam Hamelm 5mg/ml)
Ketamine 100mg/kg
(Ketalar® 50mg/ml)
IV Xylazine 10mg/kg(Rompun® 20mg/ml)
Ketamine 100mg/kg
(Ketalar® 50mg/ml)
V Medetomine 1mg/kg(Domitor® 1mg/ml)
Ketamine 75mg/kg
(Ketalar® 50mg/ml)
2.8 In VIVo transdUctions (III-V)
24 white, 11- to 13- week-old male CD-1 mice (weight approx. 30 g, Harlan, 
Netherlands) were used in the lentivirus experiment. The mice were divided into two 
groups: a kanamycin group and an untreated group. The animals in the kanamycin 
group were pretreated with kanamycin injections 15 days prior to the surgery; the 
other group received no pretreatment. Each animal in the pretreated group received 
daily 0.6 ml of kanamycin sulfate (0.02 ml/g daily, 2 x 0.3 ml/day i.p., 400 mg/
kg, Sigma-Aldrich, USA). In addition, both of these two groups were subdivided 
into three separate groups: HOX-GFP, WOX-GFP, and saline control. A total of 
six groups were formed with four mice in each group. 
One µl of pure lentivirus vector was introduced into the inner ear of the mice 
by direct microinjection through the round window membrane (III).
20 white, 11- to 13- week-old male CD-1 mice (weight approx. 30 g, Harlan, 
Netherlands) were used in the shRNA experiment. The mice were divided into 
groups according to which AAV-shRNA vector they received: p27Kip1 (AAV-p27-
shRNA), p53 (AAV-p53-shRNA), or p27Kip1+p53 (AAV-p27+p53-shRNA). The 
fourth group received only saline injections. These four groups (16 mice) were 
pretreated with kanamycin injections 15 days prior to the surgery. Each animal 
received 0.6 ml of kanamycin sulfate as described earlier. The fifth group received 
AAV-EGFP injections without kanamycin pretreatment. AAV-shRNA together with 
AAV-EGFP 0.5 + 0.5 µl, or 1 µl of saline was introduced into the inner ear of the 
mice by injecting directly through the round window membrane (IV). 
40 white, 11- to 13-week-old male CD-1 mice (weight approx. 30 g, Harlan, 
Netherlands) were used in the ribozyme experiment. The animals were divided 
into three groups (AAV-GFP, AAV-Rz, and saline) and there were four animals in 
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each group. 1 µl of virus vector (AAV-GFP or AAV-Rz) or saline was injected into 
the inner ear through the round window membrane. Those animals in whom the 
stapedial artery ruptured during the procedure were excluded from the study (V).
2.9 tissUe processinG (II-V)
In the further course of the experiment, the animals were sacrificed as follows: 
lentivirus-injected animals 14 days after the surgery (III) and AAV injected animals 
one week (V) or one month (IV,V) after the surgery.  All animals received an i.p. 
overdose of sodium pentobarbital (0.3 mg/10 g, Mebunat, Orion, Finland). After 
losing consciousness, the animals were perfused transcardially through the left 
ventricle with 20 ml of saline or PBS followed by 10 ml of 4% PFA. The inner 
ears (cochleae), and in some cases selected internal organs (brain, liver, heart, 
lungs, bladder, kidney, spleen, part of the duodenum, femoral bone marrow), were 
harvested and postfixed in 4% PFA overnight at +4ºC. The cochleae were decalcified 
in 0.5 M EDTA for 7-14 days and rinsed afterwards in PBS. All the internal organs 
were rinsed several times in PBS and left in PBS overnight at +4ºC. The brains 
were immersed in 20% sucrose in PBS (sucrose, Riedel-de Haën, Germany) and 
left overnight at +4ºC. The decalcified cochleae were mounted in paraffin (III-V) 
as also all the internal organs (III). The paraffin-embedded samples were cut into 
5µm sections.   
2.10 sample analysis (II-V)
Ten RWMs with the bony niche attached were prepared for histological analysis. 
The samples were treated accordingly (control, AgNO
3
 (5 and 20 %), trichloroacetic 
acid, or histamine-glycerol) and after the treatment washed with PBS for 10 min. The 
samples were fixed with 4% PFA overnight at 4°C, and then embedded in paraffin, 
sectioned (5µm), deparaffinized and stained with hematoxylin-eosin (Sigma). The 
slides were mounted with Permount (Fisher Scientific) (II). 
All PFA-fixed, paraffin-embedded tissue sections (cochleae and organs) were 
deparaffinized according to the following protocol: rinse in xylene (Sigma-Aldrich) 
2 x 10 min, hydration through a downward-graded series of EtOH (96%, 85%, 70%, 
50%, 30%) for 2 min each with a final rinse in PBS 3 x 5 min.
The GFP expression was detected from paraffin-embedded cochlear tissue 
sections and paraffin-embedded internal organs. The deparaffinized tissue sections 
were mounted in fluorescent Vectashield® Mounting Medium (Vector Laboratories, 
USA) under glass coverslips (III-IV).
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The antigen retrieval was performed by incubating the sections for 20 min at 
room temperature in proteinase K solution [10 µg/ml (Roche Applied Science) + 
10 mM Tris-HCl, pH 7.6] (III-IV).
CD4 and CD8-β staining: The sections were rinsed in PBS-T (Triton X-100, 
Fluka, Switzerland) 2 x 5 min and stained with rat monoclonal CD4 and CD8-β 
antibodies (2 µg/ml, Santa Cruz Biotechnology, Inc., USA) diluted in PBS-T with 
1% NRS (normal rabbit serum, from ABC kit). The sections were incubated with 
primary antibody for 24 hours in a moist chamber at +4ºC. The bound antibody was 
visualized with a Vectastain® Elite ABC kit (Vector Laboratories, USA) according 
to the manufacturer’s instructions. DAB (diaminobenzidine tetrahydrochloride, 
Sigma-Aldrich, USA) was used according to the manufacturer’s instructions for the 
localization of peroxidase in the tissue sections. Finally, all the samples were mounted 
in Permount® (Fisher Scientific, USA) under glass coverslips. The inflammatory 
reaction caused by the vectors and also the amount of inflammatory cells on the 
analyzed tissue sections were only roughly estimated according to the following 
scale: mild/few inflammatory cells, moderate/some inflammatory cells, severe/
many inflammatory cells. (III)
TUNEL-staining: Apoptosis of hair cells and of other inner ear cell types was 
detected with a fluorescence in situ cell death detection kit (Roche Applied Science, 
Germany), also called the TUNEL-staining method, according to the manufacturer’s 
instructions. After staining, the slides were mounted in fluorescent Vectashield® 
Mounting Medium (Vector Laboratories, USA) under glass coverslips. (III-V)
2.11 flUorescence microscopy (II-V)
All samples were analyzed under an Axioplan 2 fluorescence microscope (Zeiss, 
Germany). The GFP fluorescence was analyzed with a FITC filter (fluorescein 
isothiocyanate), which was combined with a standard TRITC filter set to exclude 
autofluorescence. Digital images were analyzed with the Axiovision 3.0 program 
(Zeiss, Germany).
2.12 statistical analysis (I-V)
The data from the audiological records and questionnaires were analyzed using 
Prism 3.03 for Windows. The chi-square test, Pearson’s correlation test and t-test 
were applied. P-values less than 0.05 were considered statistically significant (* 
p<0.05, ** p<0.01, *** p<0.001) (I). 
The absorbances of toluidine blue were statistically analyzed with GraphPad 
Prism software (t-test, Graphpad Software). (II)
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All TUNEL positive nuclei were counted (mean ± SEM) and the results 
statistically analysed with Student’s t-test (III-V) and ANOVA (V) (*p < 0.05, **p 
< 0.01, ***p < 0.001). (III-V)
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resUlTs anD DIsCUssIon
1. effect of cochlear implantation on the qUality  
 of life in finnish Ush3 patients (I)
1.1 Ush3 patients
Usher syndrome type 3 is the most common form of Usher syndrome in Finland. 
The patients are afflicted with hearing loss, retinitis pigmentosa and in some cases 
variable vestibular dysfunctions. They are considered to have a profound sensory 
handicap. Cochlear implants are widely used among USH3 patients. Implanted 
USH1 patients have been studied previously (Liu et al., 2005; Pennings et al., 
2006); however, this is the first study ever done on USH3 patients. Previous 
studies have shown that cochlear implantation in deaf-blind adults is as successful 
as in other prelingually and postlingually deaf adults (Loundon et al., 2003). The 
USH3 genotype of participating patients was determined from saliva samples. 
All 19 genotyped patients were of Finnish ancestry and were homozygous for the 
Finmajor mutation (p.Y176X). Although all of our patients had the same p.Y176X 
mutation in the CLRN1 gene, the hearing, speech discrimination, and the change in 
the hearing ability varied significantly after implantation. The factors which cause 
the differences in the clinical phenotype and the prognosis of the syndrome are still 
unknown. A recent study by Ebermann et al. suggests that alternative splicing of 
the USH genes or effects of modifier genes could explain some of the differences 
in the clinical phenotype (Ebermann et al., 2010). Västinsalo et al. have studied 
alternative splicing of the CLRN1 gene. Also they concluded that the structure of 
CLRN1 is more complex than previously assumed and that multiple splice variants 
of CLRN1 may explain the variation in the clinical phenotype among USH3 patients 
(Västinsalo et al., 2011).
All USH3 patients had used hearing aids prior to the cochlear implantation. 
Conventional hearing aids had been used for 30 ± 14 years and cochlear implants for 
6 ± 4 years. The mean age of the patients was 41 ± 17 years (Table 3). The implant 
devices received by these patients came from two manufacturers: 7 patients got 
multichannel devices from MED-EL and 12 patients Nucleus multichannel devices 
from Cochlear.
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CT and MRI scans were performed on all patients. All patients showed a normal 
morphology of temporal bone and inner ear. Prior to their surgery, the patients had 
also gone through electronystagmography including caloric tests. 14 patients had 
normal caloric responses, two patients had weak responses and in three patients 
the caloric responses were not evaluated preoperatively. The patients did not have 
clinical vestibular problems. 
1.2 aUdioloGical resUlts  
The mean preoperative hearing threshold of our patients one year prior to the 
surgery was 110 ± 8 dBHL (PTA, pure tone average, 0.5-4kHz), and the aided 
hearing threshold at the same time 58 ± 11 dBHL (PTA 0.5-4kHz). The postoperative 
hearing threshold was significantly better: 34 ± 9 dBHL (PTA 0.5-4kHz) (p < 0.01, 
compared to preoperative aided PTA, t-test) (Table 4). 
Speech recognition of the patients was tested with recorded Finnish bisyllabic 
words. The aided speech recognition scores demonstrated a progressive drop from 
17 ± 25% (5-10 years prior to surgery) to 4 ± 9% (one year prior to surgery). The 
postoperative recognition score with implant (0.5-1.5 years after the surgery) was 
significantly better: 52 ± 33% (p < 0.001, compared to the preoperative (0-1 year) 
value, t-test). Similar results were seen with implanted USH1 children (Liu et al., 
2008; Pennings et al., 2006). The most important predictors for the understanding 
of speech in postlingually deafened adults are the duration of the deafness and 
the residual hearing before implantation (Gantz et al., 1993; Van Dijk et al., 1999). 
Speech discrimination is significantly poorer in prelingually deafened CI recipients 
than in postlingually deafened patients. The prelingually deafened implant recipients 
are also known to have a higher rate of non-use of the implant (David et al., 2003; 
Waltzman et al., 1992). Patients who already use sign language as their primary 
mode of communication may even turn down the opportunity to receive a CI.
Table 3. USH3 patient information
Ush3 patients
n=19
age
(years)
age at 
implantation 
(years)
Use of 
conventional 
ha (years)
Use of CI 
(years)
Mean±sD 47±19 41±17 30±14 6±4
Median 51 44 29 5
Min 12 10 12 1
Max 72 64 58 13
HA: hearing aid; CI: cochlear implant
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Table 4. The preoperative and postoperative mean hearing thresholds of USH3 patients
preoperative
(5-10 years)
preoperative
(1 year)
preoperative 
with ha
(1 year)
postoperative 
with CI
(1 year)
hz dB dB dB dB
500 100±9 101±8 50±12 33±6
1000 105±7 110±8 49±12 35±8
2000 108±9 115±6 64±11 34±12
4000 105±14 114±9 69±9 33±11
pTa(0,5-4 khz) 104±10 110±8 58±11 34±9
Hz: hertz; dB: decibel; PTA: pure tone average
1.3 qUestionnaires
The GBI is a questionnaire which assesses the patient’s health status after an 
otorhinolaryngological intervention (Lassaletta et al., 2006; Robinson et al., 1996). 
The patient’s quality of life (QOL) is by the GBI questionnaire measured in three 
categories: social, general, and physical. The mean GBI total score in Finnish USH3 
patients was 30 ± 19 (median 31, min 3, max 61). The mean social subscore was 14 
± 18 and the mean physical subscore 0 ± 17. In our study the GBI total score was 
positive, which means that the patients felt that their health status had improved 
after the intervention. 
The GBI results were plotted against age of the patient (r, 0.402), age at 
implantation (r, 0.427), or against speech recognition one year postoperatively 
(r, 0.38). In our results, neither the patients’ age nor their age at implantation 
nor their speech discrimination one year after the implantation was showing any 
correlation with GBI results. The U.K. Cochlear Implant Study Group (CISG) had 
studied the benefits of cochlear implantation in 277 patients by means of the GBI 
(UK Cochlear Implant Study Group, 2004). We plotted our GBI total scores against 
the patients’ age and compared the results with the U.K. CISG’s results. Four USH3 
patients out of 19 did not fit into two standard deviations of the mean benefit of 227 
implanted patients of the U.K. CISG study. The visual scores were also evaluated: 
there was no significant difference between the current visual score and the visual 
score before the implantation. The GBI results show that USH3 patients benefit 
from the implantation as much as implanted patients with other deficits (Lassaletta 
et al., 2006). It is possible that our retrospective, cross sectional study design was 
causing bias in the results. USH3, however, is a rare syndrome and the number of 
USH3 patients is limited, and a prospective study would be impossible to execute. 
The validated GHSI form comprises 18 health status questions which evaluate 
psychological, social, and emotional aspects of QOL at the time the GHSI is 
completed. The total score of the GHSI data of hearing (59 ± 9), when compared 
to that of vision (56 ± 14), was not significant (score range 0 to +100, p > 0.05). 
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Our self-designed questionnaire gathered information about the CI and its use. 
Most of the patients (15/17, 88%) reported that they used the CI all the time or 12-
16 hours per day. Most patients (18/19, 95%) did not need any assistance in setting 
the CI. Over half of the patients (11/19, 58%) felt it easier or much easier to use a 
CI than conventional hearing aids. Most patients (11/18, 61%) did not experience 
tinnitus or did so only seldom. Those who reported tinnitus had noticed that the 
implant had an effect on tinnitus sound. 8 out of 13 (62%) patients reported that 
the cochlear implant either reduced or even stopped the tinnitus sound. 
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2. permeability of detached intact rwm an In VItro  
 model (II) 
2.1 In VItro rwm model
Previous in vivo studies have shown that the inner ear can be accessed with viral 
vectors through the RWM (Derby et al., 1999; Jero et al., 2001a; Komeda et al., 
1999; Raphael et al., 1996; Yagi et al., 1999). The role of lymphatic vessels and/or 
blood vessels in the transmission of agents to the inner ear is difficult to assess, 
which prompted a need for an in vitro model for RWM gene transfer studies. We 
created such a model by attaching intact mouse RWM to a petri dish. 
It is known that the coxsackievirus and adenovirus receptor (CAR) is responsible 
for the expansion of adenovirus infection by disrupting tight-junctions, this way 
letting the virus escape across epithelial barriers to the environment (Arnberg N, 
2009; Cohen et al., 2001; Walters et al., 2002). Histamine disrupts tight-junction 
protein expression (Flynn et al., 2009; Zabner et al., 2003) and, therefore, may 
enhance Ad-mediated gene transfer into the cochlea through the RWM. In order 
to produce changes in the membrane, we treated the outer surface of the RWM 
with AgNO
3
 (5 or 20%), trichloroacetic acid or histamine-glycerol. After treatment, 
some of the samples were sectioned and evaluated under light microscopy. Control 
samples showed a normal inner and outer surface of the RWM. After the AgNO
3
 (5%) 
treatment, we observed destruction of the outer epithelial lining. After AgNO
3
 (20%) 
treatment, all three layers of the RWM showed destruction. After the trichloracetic 
acid treatment, the outer epithelial surface was damaged. No changes could be seen 
under light microscopy after the histamine-glycerol treatment. This was surprising, 
since there are previous data which suggest that histamine causes changes to the 
RWM which lead to evident increase in permeability (Dennis et al., 1976). 
2.2 passaGe throUGh intact rwm
The role of the RWM in secretion and absorption has been known for many decades 
(Miriszlai and Benedeczky, 1978; Richardson et al., 1971). Since then, many animal 
studies have focused on the permeability of the RWM. It is known that even though 
the RWM is three-layered it behaves more like a semipermeable membrane. 
A number of agents penetrate the RWM, including antibiotics, antiseptics, 
arachidonic acid metabolites, local anesthetics, toxins, albumin, cationic ferritin, 
and horseradish-peroxidase. The permeability of the RWM is influenced by the 
agent’s size, configuration, concentration, liposolubility, electric charge, and also 
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by the thickness of the membrane itself (Goycoolea et al., 1988; Goycoolea, 1992). 
As we wanted to change the permeability of the RWM, we treated it with AgNO
3
, 
trichloracetic acid, or histamine-glycerol. Trichloracetic acid and histamine-glycerol 
reduced the permeability of the membrane, and the reduction was also significant 
with AgNO
3
 at the concentrations of both 5% and 20%. Dennis et al. suggested 
that topical administration of histamine causes vasodilated edema in the middle 
ear mucosa and also an increase in the RWM’s permeability (Dennis et al., 1976). 
Also inflammation in the middle ear mucosa is known to cause changes in RWM 
permeability; the permeability is increased at the beginning of the inflammation, but 
gradually decreases due to swelling of the RWM while the inflammation continues 
(Goycoolea, 1992). This was also seen in our results. Histamine is also known to 
disrupt tight-junction protein expression (Flynn et al., 2008; Zabner et al., 2003). 
The failure of the histamine-glycerol treatment to enhance the RWM’s permeability 
might result from a recovery tight-junction protein expression in the RWM due to 
a wronly chosen time window. 
We chose to use toluidine blue in our RWM passage experiment because of 
the small size of its molecules; Juhn et al. had reported that small molecules are 
transported quickly through the RWM (Juhn et al. 1989). The absorbance of 
toluidine blue was measured spectrophotometrically from the PBS samples we 
took from the inner ear side of the RWM model. Toluidine blue passed through 
the pretreated (AgNO
3
, trichloracetic acid, or histamine-glycerol) RWM in a time-
dependent manner. 
Also changes in osmolality can have consequences for the permeability of the 
RWM. Since the RWM is permeable to water, osmotically active substances in 
the middle ear can alter the fluid osmolality in the inner ear. This can result in 
membrane displacement (Juhn et al., 1988). To avoid this problem, both the Ad 
vector solution and the sample collection chamber contained physiological buffer. 
The passage of Ad vector through the intact RWM was studied at three different 
time points: one, three, and five days after virus administration. We detected Ad 
vectors from the samples with PCR. A previous study by Jero et al. suggested that 
Ad passes through intact RWMs in vivo (Jero et al., 2001a). Our results show that 
Ad passes through intact RWMs also in vitro. Viral transmission through the RWM 
increased during the first two days and stabilized at day three, i.e. the Ad vector’s 
passage happened in a time-dependent manner. The passage of the Ad vector was 
slower than the passage of toluidine blue. This may result from the bigger molecular 
size of Ad vector compared to toluidine blue. 
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2.3 expression of Gfp in the rwm
Evaluation of the expression of GFP was our second method of assessing the 
molecular transport through the RWM. The treated RWMs were removed from the 
petri dish at three different time points: after one, three, and five days. At day one 
the GFP expression was not yet detectable, but at days three and five the samples 
showed GFP expression in the RWM structures. GFP fluorescent cells were seen 
especially in the outer surface of the RWM. Even though Ad-GFP transduced cells 
of the RWM, the vectors also caused damage to the outer surface of the membrane. 
This may have inhibited further transfer of Ad-GFP through the membrane. Aside 
of this, it is known that first generation Ad vectors cause immune reactions in the 
inner ear (Jero et al., 2001a; Luebke et al., 2001b), while toxic effects can be avoided 
by deleting several viral genes from the vectors (Holt, 2002). 
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3. hox and wox lentiVirUses in inner ear Gene  
 transfer (III)
3.1 transdUction efficiency of hox-Gfp and wox-Gfp
Lentivirus vectors are based on the human immunodeficiency virus type 1 (HIV-1) 
and they have been studied intensely since 1996. Lentivirus vectors infect both 
dividing and nondividing cells, which makes them potential vectors for cochlear 
gene transfer. Lentivirus-mediated gene transfer is stable due to the integration 
of the vector genome into the target cell genome, by which the expression of the 
transgene is also long-term (Naldini et al., 1996). 
We tested HOX and WOX lentivirus vectors first in vitro in HeLa cell culture. 
Both vectors transduced HeLa cells. We saw a clear GFP expression in transduced 
HeLa cells after three, five, and seven days (Figure 7A). The average percentage 
of transduced HeLa cells after 7 days of incubation was 66% ± 12%. Pellinen et al. 
transduced cancer cell lines successfully with vectors similar to HOX and WOX 
lentivirus vectors (Pellinen et al., 2004). A previous study by Han et al. showed that 
SGNs and glial cells can be transduced by lentivirus vectors in cochlear explants 
(Han et al., 1999). We studied the transduction efficiency of lentivirus vectors also 
in vivo in CD-1 mice. GFP transgene expression was restricted to the mesothelial 
cells in the perilymphatic space of the cochlea (Figure 7B). Delicate, but genuine 
GFP expression was observed in the cells surrounding the scala vestibuli and scala 
tympani while the organ of Corti and the tectorial membrane did not show any 
GFP expression. Han et al. were studying lentivirus vectors in vivo in a guinea pig 
cochlea. They saw GFP expression also in the perilymphatic parts of the cochlea 
after infusion with an osmotic minipump (Han et al., 1999). Differences in the 
localization of GFP expression may result from the promoters used for transgene 
expression. Han et al. used the CMV promoter, which may have influenced the 
localization of GFP in the cochlea. A previous study by Salmon et al. indicated that 
the choice of promoter affects the level of lentivirus vector-mediated transgene 
expression in human hematopoietic stem cells (Salmon et al., 2000). We detected 
GFP expression only in the cochlear sections of animals injected with the vector. 
Untreated contralateral control cochleae showed no GFP expression. It appears 
that lentivirus vectors are mainly localized in the injected ear.
We compared the transduction efficiencies of the two lentivirus vectors. We did 
not observe any differences in transduction efficiency between the two, even though 
the WOX-GFP vector has a WPRE expression enhancer element attached to it and 
WPRE is known to increase transgene expression (Pellinen et al., 2004; Zufferey 
et al., 1999). Cochlear sections from the saline injected control mice showed no 
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GFP expression. Altogether, the results suggest that lentivirus vectors can be used 
in delivering transgene products into the perilymph.
Figure 7. Lentivirus vector mediated GFP expression
A) HeLa cells
B) Lining cells of scala tympani (arrow) 
3.2 transdUction efficiency of hox-Gfp and wox-Gfp after  
 kanamycin treatment
We evaluated the effect of the aminoglycoside antibiotic kanamysin on transduction 
efficiency because it is known that aminoglycoside antibiotics damage primarily the 
OHCs while IHCs and SCs are less affected (Murillo-Cuesta et al., 2010; Rybak, 
2007; Wu et al, 2001). Wu et al. and Murillo-Cuesta et al. were studying kanamycin 
ototoxity in CBA, C57B/6, and BALB mice (Murillo-Cuesta et al., 2010; Wu et al, 
2001) but not in CD-1 mice. We observed, in our CD-1 mice, kanamysin-induced 
apoptosis in both the IHCs and the OHCs, which is in accordance with the previous 
results. We detected apoptotic cells also in the stria vascularis and in the structures 
of the vestibular system. Further, we studied whether damage caused by kanamycin 
has any effect on the transduction efficiency of HOX-GFP and WOX-GFP but we 
saw no difference in the pattern of GFP expression between the kanamycin treated 
and the control animals.
The number of apoptotic outer hair cells, inner hair cells and vestibular sensory 
cells per section was calculated and the results statistically analyzed. The number of 
apoptotic OHCs in the HOX-GFP and WOX-GFP group were significantly higher 
than in the saline group. The WOX-GFP group also showed a significantly higher 
number of apoptotic IHCs than the saline group (Table 5).
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Table 5. Difference in the number of apoptotic hair cells in HOX, WOX, and saline groups (statistical 
significance p < 0.05) 
cells groups P value (p < 0.05)
OHC WOX vs saline p = 0.0253
HOX vs saline p = 0.0486
IHC WOX vs saline p = 0.0211
3.3 distant spread of hox-Gfp and wox-Gfp to peripheral orGans
We looked for a possible distant spread of lentivirus vectors from paraffin-embedded 
brain, liver, heart, lung, duodenum, kidney, bladder, spleen, and femoral bone 
marrow tissue sections. The sections were checked for GFP expression. The only 
expression we found was in the liver of one HOX-GFP injected animal; i.e. the 
expression was localized in the cells surrounding the portal vein. All other inspected 
tissues were free of GFP expression. Our results suggest that any distant spread of 
lentivirus vectors appears to be minimal. 
3.4 immUne responses after transdUction with lentiVirUs  
 Vectors
Inflammatory reactions in the inner ear can damage the sensory epithelia of the 
cochlea and also the vestibular system. We studied whether lentivirus vectors 
cause inflammatory reactions in the cochlea. CD4 and CD8-β antibodies will stain 
macrophages, T cells, and dendritic cells and were therefore chosen to be used in 
the experiment. Inflammatory reactions caused by other gene transfer vectors have 
already earlier been evaluated with CD4 and CD8-β antibodies (Staecker et al., 
2001). It is known that adenovirus- and herpes virus-derived vectors will cause a 
significant inflammatory reaction in the cochlea at the site of vector injection. Any 
inflammatory reactions elsewhere in the cochlea and in the contralateral cochlea 
are milder (Staecker et al., 2001). In addition, the amount of inflammatory cells 
observed in the saline control animals was equivalent to the amount detected in 
vector treated animals (Staecker et al., 2001). The new second-generation adenovirus 
vectors seem to cause a milder immune response (Bessis et al., 2004). We found 
only few inflammatory cells in the cochlear sections from the vector injected ear. 
The lymphocytes were found in the perilymphatic space of the cochlea or in the 
vestibular system, but we did not find any lymphocytes in the endolymphatic space 
of the cochlea. The detected inflammatory response to the lentivirus vectors was 
mild (Table 6), and we suggest that the injection of the vector into the inner ear 
does not increase the inflammatory reaction in the cochlea. Single lymphocytes 
were also detected in the samples from the contralateral control ears. Few vector 
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injected animals had lymphocyte aggregates in the vestibular area. However, some 
inflammatory cells are always present in the inner ear structures. We conclude that 
lentivirus vectors do not cause any significant inflammatory response in the inner 
ear, and thus provide a safe method for inner ear gene therapy. 
Table 6. Level of immunological reaction in the cochlea
Group mouse #1 mouse #2 mouse #3 mouse #4
HOX + + + −
WOX + + − +
saline + + − +
HOX with 
kanamysin
+ − + +
WOX with 
kanamysin
− + + +
saline with 
kanamysin
+ + + −
Scale: − no reaction, + mild reaction, ++ moderate reaction, +++ severe reaction 
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4. effects of aaV-shrna constrUcts on kanamycin  
 damaGed cochlea (iV)
4.1 testinG of shrna constrUcts in cos cells 
The functionality of shRNAs was tested in COS cell cultures. After 24 or 48 hours 
of incubation cells were collected and proteins extracted. In dividing COS cells no 
p27Kip1 expression was detected so that inorder to test the p27Kip1 constructs, p27Kip1 
cDNA was also co-transfected into COS cells. shRNAs were cloned into the pSilencer 
1.0-U6 vector. Western blot analysis with anti-p27Kip1 antibody showed that the best 
silencing was produced with p27Kip1 shRNAs 2 and 3. These results suggest that 
the p27Kip1 shRNAs 2 and 3 are most fitting to silence p27Kip1 expression in cells. 
Therefore, these two p27Kip1 shRNAs were first cloned together and then into the 
AAV vector (Paterna et al., 2000) to give rise to the AAV-p27-shRNA.
The p53 shRNA was tested by transfections into COS cells which express p53. 
In the Western blot analysis, proteins were also extracted from mouse embryonic 
fibroblasts (MEFs) which had been isolated from gene-targeted p53 null embryos 
(p53-/-) and heterozygous embryos (p53+/-). As expected, no p53 could be detected 
in p53-/- MEFs whereas p53+/- MEFs showed detectable levels of p53 expression. In 
COS cells the p53 expression had clearly decreased after 24 hours of transfection, 
and after 48 hours the level appeared nearly normal. This result suggests that 
the p53 shRNA can be used for silencing experiments in cells. The p53 shRNA 
fragment was cloned into the AAV vector either alone in order to give rise to the 
AAV-p53-shRNA, or together with the two p27Kip1 shRNAs 2 and 3 to give rise to 
AAV-p27+p53-shRNA.
4.2 aaV-eGfp and aaV-shrna Vector expression in moUse cochlea
Functional shRNA constructs and AAV-EGFP were injected into kanamycin-
damaged mouse cochleae through the intact RWM. The small packaging size 
(~4.7kb) of the AAV virus capsid made it impossible to combine shRNAs and EGFP 
into the same construct. Instead, the two constructs were mixed and injected at the 
same time. After a month, an EGFP expression was clearly detectable in the cochleae 
of all injected mice (Figure 8). The expression was limited to the organ of Corti and 
was seen in all cochlear turns. However, the expression was most intense at the site of 
the injection. Previous studies with AAV-GFP have shown similar results (Kilpatrick 
et al., 2011; Lalwani et al., 1998a,b). One control group of mice was injected with 
AAV-EGFP but did not receive kanamycin prior the injections. Kanamycin had no 
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effect on the expression pattern of the EGFP in the cochlea. These observations are 
in accordance with our previous results with lentivirus vectors (Pietola et al., 2008). 
The influence of shRNAs on the function of auditory epithelium was not studied. 
It is currently not known whether these shRNAs have an effect on hearing in vivo. 
Figure 8. AAV-GFP expression in mouse cochlea.
AAV-GFP expression in the inner hair cell (arrow) 
4.3 improVed cell sUrViVal in the inner ear of aaV-shrna  
 transdUced mice after aminoGlycoside damaGe
Aminoglycoside damage in the mammalian hair cells is irreversible and leads 
to sensorineural hearing loss. Aminoglycoside antibiotics are known to damage 
the OHCs, but also IHCs and SCs (Murillo-Cuesta et al., 2010; Wu et al., 2001). 
Aminoglycosides enter HCs through mechanoelectrical transducer channels and 
inside HCs they form aminoglycoside-iron complexes, which results in the formation 
of reactive oxygen species (ROS) (Rybak and Ramkuram, 2007). ROS are believed to 
promote apoptotic cell death. Apoptosis of the HCs begins at the base of the cochlea 
and spreads up to apical regions (Murillo-Cuesta et al., 2010; Wu et al., 2001). 
Cheng et al. demonstrated that deletion of the p53 offers a significant protection 
against cisplatin-induced hair cell loss (Cheng et al., 2005), and Kaur et al. found 
that siRNA against STAT1 (signal transducer and activator of transcription-1) also 
offers protection against cisplatin ototoxity (Kaur et al., 2011). Liu et al. concluded 
in their study that sustained and regulated AAV1-mediated GDNF (Glial cell-
derived neurotrophic factor) expression protected the cochlear function of rats from 
aminoglycoside-induced ototoxicity (Liu et al., 2008). Kanamycin injections caused 
apoptosis in the cochlear auditory epithelium of CD-1 mice (Figure 9). We observed 
apoptotic HCs throughout the cochlea. Kanamycin caused apoptosis in both IHCs 
and OCHs, which was predictable and consistent with our previous results about 
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lentivirus vectors and also with earlier studies with other mouse strains (Murillo-
Cuesta et al., 2010; Pietola et al., 2008; Wu et al., 2001). The degeneration of 
different inner ear cell types due to aminoglycoside damage was demonstrated by 
Tunel-staining. We found less apoptotic HCs in the AAV-shRNA injected cochleae 
than in the contralateral control cochleae and the saline injected control cochleae. 
The differences in the level of apoptosis between AAV-shRNA (p53 and p27+p53) 
and saline injected cochleae were statistically significant (Table 7). Surprisingly, the 
number of apoptotic cells in AAV-p27-shRNA injected mice was not significantly 
different from that in saline injected mice. These results suggest that silencing of 
p53 in the kanamycin treated cochleae decreases the cell death in the auditory 
epithelium.
Figure 9. Kanamycin induced apoptosis in the mouse cochlea.
Arrows show apoptotic cells in the cochlea.
Table 7. Level of apoptosis in AAV-shRNA treated cochleae compared to saline control cochleae
Constructs p value, statistical significance p<0.05
AAV-p53-shRNA vs. saline p = 0.00014
AAV-p27+p53-shRNA vs. saline p = 0.0011
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5.  effect of aaV-anti-clarin-1-ribozyme in the inner  
 ear (V)
Ribozymes can be used for a sequence-specific inhibition of gene expression, which 
makes them potentially useful for gene therapy (Birikh et al., 1997). Self-cleaving 
ribozymes are small and specific, which enhances their potential for medical 
applications (Hauswirth et al.,2000). There are two kinds of ribozymes, hairpins 
and hammerheads, which have both been used in gene therapy studies. Both catalyze 
sequence-specific cleavage of target RNA, producing molecules which contain a 
5’ hydroxyl and a 2’, 3’-cyclic phosphate. We used hammerhead ribozymes. They 
have been used more commonly because of their higher specificity to target sites 
(Birikh et al., 1997; Hauswirth et al., 2000). AAV-delivered ribozymes have not 
been studied previously in the cochlea, but Hauswirth et al. used vector-delivered 
ribozymes for the study of retinal diseases (Hauswirth et al., 2000) and Lewin et 
al. tested ribozymes in rat models of autosomal dominant RP (Lewin et al., 1998). 
5.1 cleaVaGe time coUrse reactions
Three hammerhead ribozymes were designed. They all recognized and cleaved 
wt mouse clarin-1 mRNA. The cleavage time course reactions of three candidate 
ribozymes were analyzed from a gel autoradiograph in which synthetic RNA 
oligonucleotide 12-mer substrates were used. We found that the ribozyme Rz166, 
which cuts right before the start codon following the GUC triplet, was the most 
efficient in vitro, and was consequently chosen for our in vivo studies. The ribozyme 
was attached to an AAV2 vector which had a CBA promoter.
5.2 expression of aaV-Gfp in ViVo
We studied GFP transgene expression in the wt CD-1 mouse cochlea. One week 
after the injections we saw GFP expression in the hair cells, especially in the IHCs. 
There was no expression in the SGNs. After one month, GFP fluorescence was visible 
in both IHCs and OHCs. Again, SGNs did not show any GFP fluorescence. We 
detected GFP expression in the stria vascularis and in singular epithelial vestibular 
cells after both one-week and one-month survival. However, the intensity of the 
GFP expression was variable throughout the cochlea. There was a slight decrease 
in the expression in the HCs and in the stria vascularis in the one-month samples. 
Previous studies of the expression of GFP after AAV-GFP-mediated delivery to the 
cochlea produced similar results (Kilpatrick et al., 2011; Lalwani et al., 1998a,b). 
Modification of the promoter or the AAV serotype will change the tissue specificity 
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of the vector and may cause differences in the expression strength (Bedrosian et al., 
2006; Kilpatrik et al. 2011; Liu et al., 2005; Luebke et al., 2009). AAV vector using the 
PDGF promoter allowed transduction of blood vessels in the infused cochlea (Luebke 
et al., 2001), CAG promoter (a hybrid promoter which contains sequences from CBA 
and CMV) leads to transduction of exclusively hair cells (Liu et al., 2007; Luebke 
et al., 2009), myosin VIIA promoter leads to strong and selective transduction of 
hair cells of cochlea and vestibule (Boeda et al., 2001; Liu et al., 2007), EFS and 
neuron-specific enolase promoters lead to transduction of spiral ganglion cells and 
the cells of the spiral ligament (Liu et al., 2007), GFAP promoter has been shown 
to transduce supporting cells (Rio et al., 2002). The AAV serotype has an effect on 
the transduction efficiency. Previous studies have reported transduction of HCs 
in vivo with serotypes 1, 2, 3, 5, 7, and 8 (Bedrosian et al., 2006; Liu et al., 2005; 
Luebke et al., 2009). During our own studies, we have accomplished transduction 
of HCs in vivo with serotypes 1, 2 and 8 (unpublished data; Aarnisalo et al., 2007; 
Pietola et al., 2012).
5.3 apoptosis after aaV-ribozyme treatment
One week after the AAV injection, we detected apoptosis in OHCs, IHCs and in the 
stria vascularis. We also found few apoptotic cells in vestibular epithelia, whereas 
SGNs showed no apoptosis. Apoptotic OHCs, IHCs and strial cells were found 
also one month after the injection. The difference in the number of apoptotic 
cells between the AAV-Rz and AAV-GFP groups after one-week survival was not 
statistically significant. The AAV-GFP group showed significantly more apoptotic 
OHCs and strial cells than the saline control group, and the AAV-Rz group was 
anyway showing significantly more apoptotic strial cells than the saline control 
group. We compared the number of apoptotic OHCs, IHCs and strial cells in the 
AAV-Rz and AAV-GFP groups and found that there was after one-month survival 
significantly more apoptosis in the AAV-Rz group. Comparison of AAV-GFP to saline 
control groups showed also significant differences in apoptotic IHCs and strial cells. 
This led to the comparison between one-week and one-month results (Table 
8). In the AAV-Rz group, significantly more apoptotic OHCs, IHCs, and strial cell 
were detected in the one-month samples. The vestibular epithelial cells showed no 
significant difference. In the AAV-GFP group’s one-month samples only the number 
of apoptotic OHCs was significantly increased compared to the one-week samples. 
The results suggest that the anti-clarin-1 ribozyme could initiate a process leading 
to apoptotic cell death in the cochlea. However, it is also possible that the detected 
apoptosis in the AAV-Rz group is partly an unspecific effect originating from an 
unspecific breakdown of mRNA. In this case it would not have any relation at all 
to the apoptosis caused by to clarin-1 loss. The control vector (AAV-GFP) did not 
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transduce SGNs, thus we did not observe apoptotic SGNs in the AAV-Rz treated 
group. Since we were not able to deliver the ribozyme cDNA to the spiral ganglion, 
the effect of anti-clarin-1 ribozymes in SGNs could not be evaluated. The effect of 
anti-clarin-1 ribozymes on hearing or vestibular functions was not tested and needs 
further evaluation. The clinical phenotype in USH3A is progressive, suggesting a 
degenerative process in the cochlea and retina. Our results suggest that an apoptotic 
process could partly explain the progressive nature of USH3A.
Table 8. Difference in the number of apoptotic cells in the cochlea when comparing one-week and one 
month samples of AAV-Rz and AAV-GFP groups 
(statistical significance p < 0.05, marked in grey)
1 wk vs. 1 mo IHC OHC strial cells vestibular cells
AAV-Rz p < 0.0001 p < 0.0001 p < 0.001 p = 0.837
AAV-GFP p = 0.06 p = 0.008 p = 0.823 p = 0.103
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ConClUDInG reMarKs
Usher syndrome type III (USH3) is the most common form of Usher syndrome in 
Finland. Mutations in Finnish USH3 patients are specific for the Finnish population 
which makes them an interesting research subject. All our USH3 patients were of 
Finnish ancestry and they were homozygous for the Finmajor mutation p.Y176X. 
Even though they all carry the same mutation, their phenotypes vary considerably. To 
date, only few studies have analyzed the benefits of cochlear implantation in patients 
with Usher syndrome, and a specific analysis on USH3 patients had not been done 
earlier. Audiological data, including pure-tone thresholds and speech recognition, 
were collected and analyzed. The results showed that the patients’ postoperative 
hearing with a cochlear implant was significantly better than their preoperative 
hearing with a traditional hearing aid. The speech recognition tests showed also 
significantly better results after cochlear implantation. All patients received a set of 
questionnaires which evaluated their quality of life. The GBI questionnaire evaluated 
the patients’ health status after otorhinolaryngological intervention, and the GHSI 
questionnaire contained questions about their health status. The third questionnaire 
focused on gathering information about the implantation, problems with the use 
of the cochlear implant, previous use of hearing aids, current status of vision, and 
vision-related symptoms. The GBI total score was positive, which indicates that 
USH3 patients believed that their health status was better after the implantation 
than before it. In conclusion it can be stated that cochlear implantation is beneficial 
to patients with USH3 and improves their quality of life.
Animal models are widely used in cochlear gene therapy studies. Gene transfer 
can be achieved via different routes: injection or infusion through the RWM or 
cochleostomy, or delivery through intact RWM by means of gelatin-sponge soaked 
with transgene. In order to study less invasive methods of gene transfer through 
intact RWM, we designed an in vitro model of the RWM. First, the permeability 
of the intact RWM was modified by manipulating its outer surface with AgNO
3
, 
trichloroacetic acid or histamine-glycerol. Microscopic inpection of the treated 
RWMs showed that histamine-glycerol preserved the cellular morphology of the 
RWM while AgNO
3
 and trichloroacetic acid destroyed the RWM partially or totally. 
Secondly, we wanted to test the permeability of the damaged RWM to an adenovirus 
vector. Toluidine blue was used as a control agent. We found that toluidine blue 
passed through the treated RWM in a time-dependent manner. Interestingly, 
damage to the RWM reduced by an unknown mechanism the passage of toluidine 
blue. The same experiment was repeated with an adenovirus (Ad) vector carrying 
GFP. Ad-GFP also passed through the intact RWM in a time-depended manner. 
The passage, however, was slower than that of toluidine blue. We concluded that 
64
Cochlear Gene Therapy; Viral Vectors, Gene Transfer, and Treatment Strategies for Usher Syndrome
the RWM model can be used in gene transfer studies in vitro. Treatment of the 
RWM with AgNO
3
, trichloroacetic acid or histamine-glycerol damaged the surface 
of the RWM but did not enhance the passage through the membrane.
Lentivirus vectors have been used in many types on gene transfer studies. 
Lentiviruses have the ability to infect dividing and non-dividing cells and they insert 
their genome into the host cells’ genome, which creates long and stable expression. 
Two lentivirus vectors carrying GFP transgene were studied in vivo. The vectors 
were introduced into the inner ear by direct injection through the RWM. Both 
vectors transduced cells in the scala vestibuli and the scala tympani, but not in the 
scala media. On the basis of this result it can be concluded that lentivirus vectors 
can be used in the delivery of transgenes or therapeutic agents to the perilymphatic 
space. The safety of lentivirus vectors was evaluated as well. Several peripheral 
organs were analyzed for GFP expression. Only the liver of one mouse contained 
GFP positive cells. It was concluded that distant spread via the circulatory system 
is minimal. An analysis of possible immunological reactions to the vectors showed 
that lentivirus vectors caused only minimal immune responses in the cochlea. The 
risk of disrupting the immune system within the cochlea by lentivirus delivery 
seems accordingly low.  
Specific genes can be efficiently silenced with RNA interference (RNAi), which 
can be performed by introducing vector-based short hairpin RNAs (shRNAs) into 
living cells. The hair cells in the organ of Corti are terminally differentiated. The 
post-mitotic state is maintained by cyclin-dependent kinase inhibitor p27kip1, which 
acts as a negative regulator in the cell cycle. p53 is a tumor suppressor protein 
which has a role in DNA damage-induced cell death, and it also initiates cell death 
in cochlear and vestibular hair cells. Three adeno-associated virus (AAV) vector-
delivered shRNAs were created and their effects on the damaged cochlea studied. 
We found that AAV-p53-shRNA and AAV-p27+p53-shRNA significantly reduced 
the number of apoptotic cells in the cochleae of mice after kanamycin damage as 
compared to control animals. The results suggest that shRNAs are suitable for gene 
silencing experiments in the cochlea, and that silencing of p53 seems to decrease 
cell death in the kanamycin-damaged cochlea.
Usher syndrome type III is caused by mutations in the USH3A gene which 
encodes clarin 1 (CLRN1) protein. CLRN1 is expressed in the hair cells and spiral 
ganglion cells, but the function of the protein in the ear is not known. We wanted 
to examine the effects of AAV-delivered anti-clarin ribozyme (AAV-Rz) in the organ 
of Corti in vivo. The transduction effiency of the used AAV vector was determined 
by means of the GFP transgene. GFP expression was detected in the hair cells, in 
the cells of the stria vascularis and in vestibular cells one week and also one month 
after virus injection, but not at all in spiral ganglion cells. AAV-Rz injections led to 
apoptosis in the cochlea. After one week few apoptotic hair cells and strial cells were 
detected. After one month the apoptotic inner and outer hair cells and strial cells 
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had become significantly more. The number of apoptotic hair cells and strial cells in 
the AAV-Rz group was one month after the injection also significantly higher than 
in the AAV-GFP group. There was also a significant difference in the number of 
apoptotic outer hair cells, inner hair cells, and strial cells in the AAV-Rz group after 
a week and after a month. These results suggest that AAV-anti-clarin1-ribozyme 
may cause apoptosis in the sensory epithelia. We also suggest that the apoptotic 
process could partly explain the progressive nature of USH3.
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